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ABSTRACT 
Patients with neuromuscular disorders such as idiopathic inflammatory 
myopathies experience a loss of muscular strength and a deficiency in intra-muscular 
creatine and phosphocreatine levels. Inflammatory myopathies affect people of all ages, 
and little is known about which therapy is optimal. In many cases patients become 
resistant to the prescribed therapies causing performance to decline. Creatine 
monohydrate has been proposed as an alternative natural treatment to the currently 
available drug therapies. 
Recent long- and short-term supplementation studies involving patients with 
various neuromuscular disorders have reported increases in muscular strength and 
enhances in body composition. These improvements are possibly due to an increased 
intra-muscular creatine store and rate of phosphocreatine resynthesis. 
The purpose of this investigation was to examine the effects of a twelve-week 
program of creatine monohydrate supplementation, combined with a resistance-training 
programme, on muscular mass and strength in knee extensors and flexors in patients 
with inflammatory myositis by restoring intra-muscular creatine and phosphocreatine 
levels. 
Patients (n = 3) received 20 g·d- 1 of creatine monohydrate for the first two weeks 
followed by 5 g·d- 1 for the remaining period. A control group (n = 7) of similar 
demographics was tested for comparison between disease and non-disease. In 
conjunction with the supplementation the subjects participated in a resistance-training 
program. The training involved knee flexor and extensor exercises 3 d·wk- 1• The 
subjects were allocated a limb to exercise whilst the untrained limb rested, serving as a 
within-subject control. 
Measurements of neuromuscular performance, isometric and isokinetic strength 
and a fatigue test were assessed throughout the study at given angles and velocities. 
Body composition was performed pre- and post-supplementation, using a dual energy x­
ray absorptiometer, as well as fingertip blood samples to test for creatinine. 
After twelve-weeks of supplementation and training, there were no signs of 
increased disease activity. The patients all noted a considerable improvement in their 
general wellbeing, resulting in reduced medications being reported. 
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No significant changes occurred for any of the parameters. However isometric 
peak torque increased for both the patient (30.7% and 2.2%) and control group (6.7% 
and 0.5%) at an angle of 60° for trained and untrained limbs respectively. Isokinetic 
peak torque also increased in the trained limbs of the patient (7.8%, 23.3%, 7.3% and 
8.8%) and control group's extensors (24.8%, 14.7%, 0.6% and 8%) at 60, 120, 180 and 
240° s- 1• The fatigue index for the patient group decreased for the trained limb (-8%) 
although increased for the untrained limb (1 % ) and the control group increased slightly 
(0.3% and 5%) for both trained and untrained limbs. 
Lean body mass increased (2.1 % and 4.3%) and fat mass decreased (2.9% and 
1.7%) for patient and control groups respectively. There were no significant changes in 
creatinine concentrations, increasing by 14.8% and 15% for the patient and control 
group with the controls being 11 % higher than the patient group at baseline and week 
twelve. 
The results indicate that a low intensity, home-based resistance-training 
programme can be safely employed for patients with stable, inactive inflammatory 
myopathies, with small non-significant improvements in muscle function and 
endurance. 
Keywords: Idiopathic inflammatory myopathy; Polymyositis; Dermatomyositis; 
Weight training; Creatine monohydrate supplementation; Muscle strength; Muscle 
mass; Muscle endurance; Body Composition. 
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CHAPTER ONE 
1.1 Background 
1. INTRODUCTION 
Myopathy is derived from the Greek phrase "disease of muscle". 
Myopathies are diseases that cause abnormal conditions with the tone and 
contraction of skeletal (voluntary) muscle. Myositis, Greek for "muscle 
inflammation", is a form of muscle disease known as Idiopathic 
inflammatory myopathy (IIM) ( cited in 1995). Idiopathic inflammatory 
myopathies are a heterogenous group of systemic diseases that fall into three 
categories, Polymyositis (PM), Dermatomyositis (DM) and Inclusion Body 
Myositis (IBM) (Brouwer et al., 2001; Lam pa, Nennesmo, Einarsdottir & 
Lundberg, 2001). 
Inflammatory myopathies (IM) affect one in every 100 000 
individuals with a prevalence rate in PM of six in every 100 000 (Chen, Wu 
& Shen, 2001; de Oliveira Karnikowski, Costa, Osella & de Toledo 
Nobrega, 2002). The incidence rates of PM and DM in the United Kingdom 
vary between an estimated 1.9 and 7.7 per million each year (Choy & 
Isenberg, 2002). Oddis, Conte, Steen and Medsger (1990) performed a 
twenty year study on hospital diagnosed cases of PM and DM in the United 
States of America and found an annual incidence rate of 5.5 in every million 
between 1952 and 1963. However it is believed that these figures are 
underestimated due to the number of IIM going undiagnosed (Choy & 
Isenberg, 2002). 
Polymyositis and DM are the most common type of IIM with PM 
being the most misdiagnosed due to its similarities with other diseases 
(Hilton-Jones, 2003). The aetiology of the disease remains to be fully 
elucidated. Although it has previously been suggested that PM is caused by 
various autoimmune disorders and immunodeficiencies, as supported by the 
presence of T cell-mediated myocytotoxicity, the complement-mediated 
microangiopathy and the existence of various autoantibodies to nuclear and 
cytoplasmic antigens are frequently found in the system (Hirakata, 2000; 
Rosenkranz, 2002; Hara et al., 2003). It is also increasingly apparent that 
these diseases develop in genetically vulnerable individuals after exposure 
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to environmental agents that stimulate immune activation and inflammation 
(Miller, 1993). 
Polymyositis rarely affects people under the age of twenty however 
cases of childhood and infant PM have been reported (Rosenkranz, 2002). 
Polymyositis is commonly found in adults aged between 30 and 60 years 
(Belostocki & Paget, 2002; Wortmann, 2002), DM, on the other hand, 
exhibits a peak initially in childhood (5 - 15 years of age) and again in 
adulthood ( 45 - 65 years) (Belostocki & Paget, 2002; Figarella-Branger, 
Civatte, Bartoli & Pellissier, 2003). More females are afflicted with PM and 
DM than males, with the ratio of female to male being two to one (Choy & 
Isenberg, 2002; Rosenkranz, 2002). 
The literature is replete with gender and age related studies 
highlighting the effects of creatine (Cr) and the creatine kinase (CK) 
reaction in healthy and diseased populations (Wyss & Kaddurah - Daouk, 
2000). The majority of research focuses on Cr monohydrate (CrM) 
supplementation as a disease preventer and a form of non-steroidal, or 
natural treatment in already diagnosed populations (Willer, Stucki, 
Hoppeler, Bruhlmann & Krahenbuhl, 2000). Recently, CrM 
supplementation has been used in select patient populations (e.g. patients 
with neuromuscular disorders) in an attempt to inhibit the progression and 
severity of the disease (Terjung et al., 2000). 
Muscle weakness, atrophy and fatigue are common impairments in 
neuromuscular diseases (Tamopolsky & Martin, 1999; Persky & Brazeau, 
2001). Recent evidence suggests that these patients have the potential to 
benefit from CrM supplementation based on the hypothesis that increasing 
the intramuscular Cr concentrations increases the Cr levels in the blood, the 
transport of Cr in the cells, the availability of phosphocreatine (PCr) and 
enhances muscle mass (Benzi, 2000; Persky & Brazeau, 2001 ). 
It has been reported in studies of elderly subjects that the greatest 
benefits from CrM ingestion are seen in people with initially low levels of 
intramuscular Cr (Volek, 1999). Patients with IM, muscular dystrophy, 
mitochondrial cytopathies and other neuropathies are reported to have lower 
intra-muscular levels of adenosine triphosphate (ATP) and PCr when 
compared with that of normal populations (Tamopolsky & Parise, 1999). 
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Therefore, it is believed that these patients stand to derive the greatest 
benefits from CrM supplementation regimens (Spector et al., 1997), without 
resulting in severe physical disabilities and suffering many of the 
deleterious side effects associated with various prescribed drug therapies 
(i.e. steroid myopathy) (Lundberg & Chung, 2000; Hara et al., 2003; 
Bromberg & Carter, 2004). Creatine monohydrate supplementation in 
conjunction with a strength training program has also been reported to 
provide further benefits in these patient populations by delaying the onset of 
muscular weakness and atrophy (Spector et al., 1997). 
1.2 Purpose of the Study 
The aim of the study was to determine whether CrM supplementation 
and physical training leads to an increase in exercise performance, muscle 
mass and strength in patients with PM and DM. 
1.3 Significance of the Study 
Creatine monohydrate supplementation has been shown to increase 
strength and muscular performance in several studies of young healthy 
subjects (Balsom, Ekblom, Soderlund, Sjodin & Hultman, 1993; Bermon, 
Venembre, Sachet, Valour & Dolisi, 1998; Tamopolsky & Martin, 1999) 
and in studies of elderly individuals (Rawson, Wehnert & Clarkson, 1999; 
Chrusch, Chilibeck, Chad, Davison & Burke, 2001). In these cases CrM 
supplementation is not only aimed at enhancing muscular performance in 
young subjects, but the ability to carry out daily tasks, such as cleaning the 
house, or participating in various physical activities for the elderly. 
In addition to the positive influences of CrM supplementation m 
muscular performance, the therapeutic value of exercise training has also 
shown to enhance muscular strength and muscular endurance in the elderly 
(Chrusch et al., 2001; Fatouros et al., 2002; Ferri et al., 2003) and for 
patients with various neuromuscular disorders (Spector et al., 1997; 
Tamopolsky, Roy & MacDonald, 1997; Louis et al., 2003). Exercise has 
been shown to reduce the risk of cardiovascular disease (Alexanderson, 
Stenstrom & Lundberg, 1999) and slow down the unavoidable loss of 
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muscle mass and muscular function associated with ageing and more 
importantly with muscle diseases (Wiesinger et al., 1998a). 
Due to the disease aetiology of PM and DM not being entirely 
understood and the positive outcomes of CrM and exercise with healthy and 
elderly individuals, further investigation is warranted as to the effectiveness 
of the two regimens on PM and DM. 
A better understanding of the disease will be extremely useful when 
considering natural therapies. Non-pharmacological therapies have received 
little attention concerning muscle diseases. The few studies available 
concerning alternative treatments often include small numbers of patients 
with a variety of diseases. There is a lack of studies primarily targeting PM 
and DM. Gaining a deeper understanding of non-steroidal therapies, such as 
CrM and exercise, and any effects on muscular function may be extremely 
useful for doctors when prescribing treatments for individuals suffering with 
muscular diseases. 
By developing a safe and effective regimen, other researchers may 
also benefit from this study by reproducing the study with other populations. 
The information obtained will hopefully, prove valuable for other patient 
populations that suffer with similar symptoms. 
1.4 Research Questions 
1. Will three months of CrM supplementation and resistance training 
(RT) cause an increase in muscle mass, strength, and endurance of 
patients with PM and DM? 
2. Will three months of CrM supplementation combined with RT improve 
muscle mass, strength or endurance of the trained limb versus 
non-trained limb? 
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1.5 Abbreviations 
ADP Adenosine Diphosphate 
ANOVA Analysis of Variance 
ATP Adenosine Triphosphate 
BL Baseline 
BWR Best Work Repetition 
B2 Biodex System 2 
B3 Biodex System 3 Pro 
CG Control Group 
CGT Control Group Trained 
CGU Control Group Untrained 
CK Creatine Kinase 
Cr Creatine 
CrM Creatine Monohydrate 
Crn Creatinine 
DEXA Dual Energy X-ray Absorptiometry 
DM Dermatomyositis 
ECU Edith Cowan University 
FFM Fat Free Mass 
FM Fat Mass 
IBM Inclusion Body Myositis 
ICC Interclass Correlation Coefficient 
IIM Idiopathic Inflammatory Myopathy 
IM Inflammatory Myopathy 
IVIg Intravenous Immunoglobulin 
JDM Juvenile Dermatomyositis 
LBM Lean Body Mass 
MCG Matched Control Group 
MVC Maximal Voluntary Contraction 
p Probability 
PCr Phosphocreatine 
PG Patient Group 
PGT Patient Group Trained 
PGU Patient Group Untrained 
PM Polymyositis 
PT Peak Torque 
ROM Range of Movement 
RT Resistance Training 
SCGH Sir Charles of Gairdner Hospital 
SD Standard Deviation 
SEM Standard Error of the Mean 
STW Set Total Wark 
TCr Total Creatine 
TW Total Work 
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1.6 Definitions 
Adenosine Diphosphate A compound consisting of adenosine and two phosphates 
Adenosine Triphosphate A compound consisting of adenosine and three phosphates 
Atrophy Decrease in cell/tissues associated with pathological conditions 
Coefficient of Variation A measure of the deviation of a variable from the mean 
Concentric Contraction A contraction in which the muscle shortens 
Creatine Kinase An enzyme that catalyses formation of PCr from ATP and Cr 
Creatine A natural nitrogenous compound serving as an energy reserve 
Creatinine A by-product of Cr metabolism 
Dermatomyositis An inflammatory disease of connective tissue marked by swelling, 
dermatitis and proximal muscle weakness 
Dry Weight The weight of material remaining after the removal of water 
Endurance Ratio The average of PT in the last five contractions divided by the 
average of the first five contractions expressed as a percentage 
Fat Free Mass/ Fat Mass Lean soft tissue/ Fat soft tissue 
Idiopathic Inflammatory A group of muscle diseases, DM, PM and IBM, characterised by 
Myopathy the inflammation of skeletal muscle 
Correlation Coefficient The degree to which two variables are related 
Isokinetic Maximum contraction to an accommodating resistance 
Isometric Muscle tension/contraction without any change in muscle length 
Myositis Inflammation of muscle tissue 
Microangiopathy Any disease of the capillaries 
Myocytotoxicity Destruction of muscle fibres 
Phosphocreatine An endogenous substance found in striated muscle. Synthesised 
and broken down to buffer ATP concentration, and acts as an 
immediate energy reserve for muscles 
Polymyositis An inflammatory condition characterised by progressive 
symmetrical weakening of the skeletal muscles 
Power The amount of work done 
Standard Deviation The degree of deviation from the central tendency 
Standard Error of the A statistical index of the probability that a given sample mean is 
Mean 
representative of the mean of the population used 
Torque A force which causes something to rotate 
Work A measure of the energy used by muscles under test conditions 
7 
CHAPTER TWO 
2.1 Crea tine 
2. LITERATURE REVIEW 
Creatine was first discovered in meat products in 1835 by a French 
scientist Chevreul (Silber, 1999). It was termed Cr coming from the word 
'kreas ' which is Greek for 'flesh' (Wyss & Kaddurah - Daouk, 2000). In 
184 7, Liebig showed that Cr could be extracted from several muscles of the 
body but not from the organs he thought to be involved (Greenhaff, 1995). 
Work by Eggleton and Eggleton (1927) as well as Fiske and Subbarow 
(1927) saw the discovery of PCr ( cited in Wyss & Schulze, 2002). Due to its 
unstable nature PCr was also termed 'phosphagen' (Wyss & Schulze, 2002). 
Lohmann discovered ATP in 1929 (Silber, 1999), shortly after Lundsgaard 
(1930) examined the PCr breakdown and its importance in supplying energy 
for muscle contraction, the two discoveries saw the discovery of the CK 
reaction later revealed by Lohmann in 1934 (Wyss & Schulze, 2002). 
Creatine is an amino acid derivative that is synthesised to form acetic 
acid - (a - methylguanidine) (Bemben, Bemben, Loftiss & Knehans, 2001a). 
Creatine is produced in the liver (hepatocytes), pancreas (islet alpha cells) 
and the kidneys (cortex and the proximaltubule) (Maughan, 1995; Feldman, 
1999). It is a non-essential dietary element found primarily in meat 
(preferably raw), eggs, fish and poultry (Bemben, Tuttle, Bemben & 
Knehans, 2001; Metzl, Small, Levine & Gershel, 2001). For an average 
male weighing 70 kilograms the nutritional requirement of Cr is 
approximately 2 g·d- 1 , but for most individuals the average intake of Cr 
through diet is 1 g·d- 1 (Harris, Soderlund & Hultman, 1992; Bird, 2003). 
This value is much lower for vegetarians and other individuals who 
consume little or no meat (Andres, Sacheck & Tapia, 1999). 
Creatine is transported from its primary site of synthesis through the 
bloodstream in the plasma at a concentration of 50 - 100 micromols per litre 
(mol/L) (Andres et al., 1999). A sodium dependent neurotransmitter 
transporter on the muscle membrane helps to facilitate its uptake for storage 
in various tissues (Volek, 1999; Willoughby & Rosene, 2001 ). The total Cr 
(TCr) found in humans' ranges between 120 - 150 grams (Bemben et al., 
2001 ). About 60% of this is found in skeletal muscle in the form of free Cr 
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and PCr (Stout, Eckerson, May, Coulter & Bradley-Popovich, 2001). These 
values tend to vary slightly between each study due to individual variability 
and differences in diet and muscle fibre composition (Maughan, 1995). 
2.1.1 Creatine Kinase 
Creatine kinase is an enzyme that catalyses biochemical reactions that 
occur intra-muscularly. The primary role of CK is to convert a phosphate 
group to Cr, resulting in a high-energy molecule PCr. Creatine kinase is also 
used in many research and clinical studies, as it is an imprecise indication of 
skeletal muscle microtrauma (Lundberg, 2001). Creatine kinase is normally 
found in muscle, when the muscle is damaged due to injury, unaccustomed 
exercise or increases in the intensity or volume of exercise. Muscle cells 
start to breakdown and the components start circulating through the 
bloodstream. A rise of CK levels in the blood is a sign that muscle damage 
is occurring or has occurred (Raastad & Hallen, 2000; Schwane, Buckley, 
Dipaolo, Atkinson & Shepherd, 2000). This peak can occur anywhere from 
six hours to five days after exercise (Raastad & Hallen, 2000). Measures of 
CK is also used as an indicator of existing muscle disease severity in the 
assessment and management of PM and DM (Kiely, Bruckner, Nisbet & 
Daghir, 2000; Chung, Wassif, Bell, Hurley & Scott, 2003). 
2.1.2 Creatine Kinase Reaction 
Creatine is often termed as an 'ergogenic' ,  Greek phrase meaning 
'work production', as it has a positive effect on muscle metabolism 
(Pepping, 1999). Muscles need energy to be able to function, they obtain 
this energy through the intracellular breakdown of ATP to adenosine 
diphosphate (ADP) (Maughan, 1995). Creatine is primarily responsible for 
the ATP re-synthesis in skeletal muscle (Walter et al., 2000). When ATP is 
stripped of a phosphate molecule to form ADP free energy is released to 
perform mechanical work. Creatine is known to have a high phosphate 
transfer potential and therefore, is very efficient in phosphorylating ADP 
(Volek et al., 1997). 
During high intensity exercises that last up to five seconds, muscle 
ATP remains fairly constant as PCr, the primary fuel reserve during 
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anaerobic exercise, levels drop almost to zero (Biwer, Jensen, Schmidt & 
Watts, 2003). The decrease of PCr during exercise is due to its involvement 
in replenishing ATP and ADP reserves (Andres et al., 1999). This is done 
via the CK reaction (PCr + ADP + Hydrogen � ATP + Cr) by which ADP 
is re-phosphorylated back into ATP (Metzl et al., 2001; Bemben et al., 
2001a). The energy released from ATP in this reaction can generate enough 
power for four seconds of muscle contraction (Feldman, 1999; Bird, 2003). 
During recovery after strenuous exercise, the CK reaction is reversed to 
produce PCr and ADP. 
The importance of the PCr system is its buffering ability of ATP use 
(Bemben et al., 2001). Phosphocreatine also facilitates energy translocation 
from the mitochondria to various sites of ATP utilisation, this is referred to 
as the PCr energy shuttle (Bemben et al., 2001a). This process helps to 
secure the availability of energy for work (Maughan, 1995; Edwards, 
Rhodes, McKenzie & Belcastro, 2000). 
2.1.3 Creatinine 
Creatine metabolism and production results in a waste product called 
creatinine (Cm) (Benzi, 2000). The daily requirement of Cr supplied by 
one's diet can be measured by the renal excretions of Cm or in blood 
samples. Normal plasma Cm values for males range between 44 - 97 µmol/1 
and values for females range between 44 - 80 µmol/1 (Bomer, Szasz, 
Bablak & Busch, 1979). Values outside these ranges can be due to age, 
varying pH levels and certain illness, which can cause the levels to be 
depressed or elevated. Like CK, Cm can be found in muscle and a rise in the 
levels of Cm in the blood is also an imprecise indicator of muscle damage. 
In the absence of CrM supplementation, muscle Cr stores breakdown 
at a constant rate of approximately 2 g·d-1 into Cm (Volek, 1999). This 
amount must be replenished from dietary sources or by endogenous 
synthesis to maintain the constant body pool of intra-muscular Cr and PCr 
(Feldman, 1999). 
Creatinine does not remain in the muscle it diffuses out of the cells 
into the blood stream. From here it enters the kidneys where it is removed 
by glomerular filtration and to a minor degree by tubular secretions. 
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Creatinine is not reabsorbed back into the body by the renal tubules and is 
rapidly excreted in urine via the kidneys (Wyss & Kaddurah - Daouk, 
2000). 
Muscles normally become saturated with Cr at 160 mmol·kg- 1 of dry 
muscle, close to a 30% increase from resting values (Andres et al., 1999). 
Previously any extra Cr, due to supplementation, that was not used by the 
muscles was thought to be converted to Cm and readily excreted by the 
kidneys, as there is no renal threshold for the urinary excretion of Cm 
(Feldman, 1999). However one recent study by Chung, Wassif, Bell, Hurley 
and Scott (2003) claimed that in healthy individuals kidneys have a Cr 
excretion threshold of about 0.05 mM/L and that any extra circulating Cr 
can lead to a condition called creatinuria. However, no evidence of Cr 
biosynthesis was found by Chung et al. (2003), therefore suggesting the 
creatinuria observed was cause by other means. 
Creatine uptake and use is regularly measured by the amount of Cm 
found in urine samples; for example, urinary excretion have previously 
indicated that the greatest Cr uptake usually occurs within the first two days 
of supplementation (Odland, MacDougall, Tamopolsky, Elorriaga & 
Borgmann, 1997). This method, however, is also a very imprecise 
measurement as endogenous Cm excretion varies among individuals due to 
physical activity, maturity, metabolic state and gender (Lukaski, 1997). 
2.2 Creatine Supplementation 
Creatine monohydrate supplementation has been shown to increase 
pre-exercise intra-muscular stores of PCr improving muscular performance 
during exercise (Rossiter, Cannell & Jakeman, 1996; Armsey & Green, 
1997). Casey, Constantin-Teodosiu, Howell, Hultman and Greenhaff (1996) 
stated that the 30% decrease in muscle ATP as a result of short high 
intensity exercise together with the increased work performed indicated that 
ADP rephosphorylation improved as a result of CrM supplementation. 
In healthy subjects, several studies have demonstrated ergogenic 
benefits of CrM supplementation on muscular mass and strength. Harris, 
Soderlund and Hultman ( 1992) performed one of the first studies on CrM 
supplementation. They investigated the absorption rates of short term CrM 
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supplementation on intramuscular levels, as well as the effects exercise may 
have on CrM uptake. Harris et al. (1992) demonstrated that supplementation 
of CrM (20 - 30 g·d- 1 ) for two or more days resulted in a significant 
increase in TCr levels of the quadriceps femoris muscle in 17 subjects 
(Females = 5; Males = 12). The greatest of these increases (up to 50%) were 
seen in subjects with initially lower intramuscular TCr pools (Harris et al., 
1992). 
In another study, men aged 19 - 60 years were found to have elevated 
their muscle Cr stores by 20% with as much as 20% stored in the form of 
PCr after ingesting 20 g·d- 1 of CrM for five days or 3 g·d- 1 for thirty days 
(Hultman, Soderlund, Timmons, Cederblad & Greenhaff, 1996). They 
showed that muscle Cr levels increased as a result of CrM supplementation 
(25 g·d- 1 for five days) and intra-muscular Cr was shown to increase by 
20%, reaching a TCr pool of about 150 - 160 mmol·kg- 1 of dry weight 
(Hultman et al., 1996). The TCr levels were also shown to increase by about 
20 - 40 mmol·kt 1 of dry weight in a study conducted by Urbanski, Loy, 
Vincent and Yaspelkis (1999), after the subjects ingested 20 g·d- 1 of CrM 
for five days. 
Stout, Eckerson, May, Coulter and Bradley-Popovich (2001) 
demonstrated that CrM supplementation during RT resulted in greater 
increases in fat free mass (FFM), muscular strength and training volume 
compared with training alone. Various studies, such as Tamopolsky and 
Parise (1999), suggest that low muscle PCr levels contribute to fatigue in 
daily activities and that this may be avoided by increasing the PCr levels 
through CrM supplementation. 
Ingesting CrM is thought to decrease the dependency on anaerobic 
glycolysis, a process that promotes the onset of fatigue by the build up of 
lactate and hydrogen ions. Creatine monohydrate supplementation also 
enhances the CK reaction and allows for greater training through increases 
in FFM (Andres et al., 1999). The increase in body mass and FFM may also 
be due to the increase in total body water, muscle fibre size and protein 
synthesis. 
Haussinger, Roth, Lang and Gerok (1993) view Cr as an osmotically 
active substance that can change the intra-cellular levels of Cr, including 
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cellular swelling which is believed to lead to increased protein synthesis 
(Andres et al., 1999). This idea is supported by reports of lowered urinary 
output and an increase in body mass during CrM supplementation as a result 
of water retention (Hultman et al., 1996). 
In addition, Preen, Dawson, Goodman, Lawrence, Beilby and Ching 
(2001) have reported findings that suggest CrM supplementation is 
associated with increased protein synthesis, which may also be responsible 
for the elevations in body mass observed in the Cr groups. Other authors 
report this increase in body mass to be due to an increase in dry mass 
growth in association with normal fluid levels in the body and not that of 
water retention (Francaux, Demeure, Goudemant & Poortmans, 2000). 
Possible mechanisms responsible for the ergogenic effect of CrM 
supplementation include increased intramuscular PCr, improved buffering, 
enhancement of Mitochondrial CK activity and stimulated biosynthesis of 
muscle myosin (Berman et al., 1998). These mechanisms accelerate the rate 
of ATP re-synthesis, enhancing recovery and resulting in an improved 
muscular performance (Schilling et al., 2001). 
2.2.1 Long and Short-term Supplementation 
Short-term (five - seven days) CrM supplementation studies have 
been shown to increase both lean body mass (LBM) and intra-muscular TCr 
stores (Balsam et al., 1993; Kreider, 1998). Kreider et al. (1998) reported a 
0.6 - 1.1 kilogram increase in body mass. However, numerous authors 
suggest that the increases are the result of increased total body water content 
rather than an increase in myofibrillar protein synthesis (Rawson & 
Clarkson, 2000). 
Long-term (> four weeks) CrM supplementation studies of healthy 
individuals show greater gains in strength and LBM (Kreider, 1998) than 
studies that last only five to fourteen days (Volek et al., 1997). Long-term 
supplementation of CrM (25 g·d-1 for five - seven days and 2 - 5 g·d-1 for 
up to twelve-weeks), is known to promote significant gains in strength, 
LBM and FFM in conjunction with a training program in comparison to 
placebo controls (Kreider, 1998). Pepping (1999) suggested that these 
improvements be mainly due to the uptake of amino acids into contractile 
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muscle proteins thus stimulating protein synthesis. However, not all studies 
have found the same enhanced performance with supplementation 
(Stevenson & Dudley, 2001). 
2.2.2 Loading 
There is a vast variation in the required dosage of many studies, which 
leads to dispute as to what dosage is the safest and most effective. Loading 
phases of 20 g·d- 1 is popular in many research studies of older individuals 
and people with diseases (Schilling et al., 2001). This dose has been shown 
to increase TCr and intramuscular PCr levels by up to 30% and Cr levels 
from 50 - 100 µmol/L to over 500 µmol/L (Ziegenfuss, Lowery & Lemon, 
1998). However, similar effects can be found in younger and healthier 
subjects with lower doses of CrM (3 g·d- 1 ) by extending the 
supplementation period (Juhn, 1999; Terjung et al., 2000). 
It can take approximately two days for supplementation to increase 
levels of muscle Cr and PCr above baseline (BL) levels and four - seven 
days for muscle performance to be increased (Andres et al., 1999; Y quel, 
Arsac, Thiaudiere, Canioni & Manier, 2002). The Cr levels in muscle can 
increase as much as 20 - 50% after initial loading, this is dependant on 
pre-existing levels (Feldman, 1999). 
Volek et al. ( 1999) have shown that as little as 2 g ·d- 1 of CrM ingested 
can maintain intra-muscular Cr levels in men who are not exercising 
vigorously. Harris et al. (1992) found that four to six doses of 5 g·d- 1 of CrM 
for two days produced a significant increase in TCr stores in the quadriceps 
femoris muscle of seventeen subjects. Again the greatest improvements 
were seen in subjects with an initially low TCr content (Harris et al., 1992). 
It has been suggested that the lower the supplement dose the less 
likely it is to develop side effects (Schilling et al., 2001 ). However, it is 
possible that dosage for the elderly needs to be extended and measured 
above the standard dosage of younger healthier subjects due to older 
individuals' displaying a lower absorption rate. 
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2.2.3 Wash Out Period 
After CrM supplementation muscle Cr concentrations can remam 
elevated for weeks, even months depending on the initial dosage ingested 
(Maughan, 1995). The period it takes for BL values to return is often 
referred to as the wash out period. 
After a brief period of supplementation TCr levels and Cr synthesis 
have been found to return to pre-existing values (Terjung et al., 2000). 
Andres, Sacheck and Tapia ( 1999) reported that after one week most of the 
ingested CrM was excreted as Cm. Feldman ( 1999) and Wyss and 
Kaddurah - Daouk, (2000) stated that Cr and PCr concentrations returned to 
BL levels approximately thirty days after brief CrM ingestion ceased. On 
the other hand, Vandenberghe et al. ( 1997) found that muscle PCr and 
urinary Cr and Cm excretion returned to normal values after four weeks of 
long-term CrM supplementation was stopped. 
In contrast, Rawson, Persky, Price and Clarkson (2004) found that 
thirty days washout was insufficient in returning muscle PCr levels to BL 
following short term CrM supplementation of 20 g ·d- 1 for five days. It did 
however report that plasma and urine Cr levels returned to BL levels within 
this period (Rawson et al., 2004). 
2.2.4 No Ergogenic Effect 
Many reports have indicated that CrM supplementation does not 
improve exercise performance (Y quel et al., 2002). Creatine monohydrate 
supplementation has shown to be less ergogenic when the supplementation 
regimens are short term and involve supplementing less than 20 g·d- 1 or with 
regimens that do not have an initial loading phase (Kreider, 1998). 
Edwards, Rhodes, McKenzie and Belcastro (2000) found no 
improvements in the repeated, anaerobic running performance of eleven 
moderately active males ingesting 20 g·d- 1 of CrM for six days. A study by 
Stevenson and Dudley (2001)  reported that CrM supplementation did not 
increase levels of PCr use or recovery during maximum voluntary 
contractions (MVC's) and dynamic muscle strength or endurance 
measurements. Stevenson and Dudley (200 1)  performed this double-blinded 
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placebo experiment on a group of resistance trained males and females. 
They concluded that CrM loading did not provide an ergogenic effect for 
unilateral knee extension exercises or electrically stimulated isometric knee 
extensions and suggested that CrM loading may even slow PCr 
replenishment (Stevenson & Dudley, 200 1 ) . These negative findings may be 
due to a CrM loading phase of only one week with no maintenance phase to 
ensure adequate Cr uptake. 
Failure to produce ergogenic effects of CrM supplementation may be 
due to the inadequate muscle Cr accumulation in subjects (Volek, 1 999) . 
Other causes could be due to the familiarisation of the subject with the 
equipment prior to testing, time of day when testing occurs, number of 
subjects involved, drug and nutrient intake prior to the trial, the length of 
supplementation anct' the type of exercise evaluated (Kreider, 1 998; 
Tamopolsky & MacLennan, 2000). 
2.2.5 Side Effects 
Creatine monohydrate is known as a relatively ' safe' supplement due 
to its low molecular weight ( 149 . 1 5) which allows for its non-toxic removal 
by the kidneys via diffusion (Bemben et al. , 2001 a). However, there have 
been negative reports, although few, of potential health implications in 
connection with CrM supplementation (Terjung et al. ,  2000). Anecdotal 
reports suggest that CrM supplementation is a potential hazard to the human 
body as it is believed to promote the incidence of muscle strains and pulls 
(Waldron et al. , 2002). It is believed that supplementation places large 
amounts of stress on bones, joints and ligaments because of the rapid gains 
in strength and body mass. Other reported side effects include nausea and 
skin rashes (Rawson et al., 1 999; Schilling et al. , 2001 ). 
Long-term effects of CrM supplementation on the liver, heart and 
kidneys have recently been of concern (Benzi, 2000). Poortmans and 
Francaux (1 998) found that CrM ingestion increased the susceptibility of an 
individual to gastrointestinal dysfunction and cardiovascular problems. 
Chrusch, Chili beck, Chad, Davison and Burke (2001 )  reported minor side 
effects as a result of CrM supplementation (i.e. loose stools, cramping, pulls 
or strains). However, these negative effects were not serious enough to 
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impair performance measured in the study and have been considered as 
isolated incidences (Persky & Brazeau, 2001). Given the little evidence in 
the literature of harmful side effects to date, further research into the long 
term side effects of CrM supplementation are needed (Andres et al., 1999; 
Lehmkuhl et al., 2003). 
A recent study by Brenner, Rankin and Sebolt (2003) found no 
indications of liver or kidney trouble with CrM supplementation (20 g·d- 1 
for one week followed by 2 g·d- 1 for four weeks) in women over a five week 
supplementation period. Kreider et al. (2003) examined the effects of long 
term CrM supplementation on blood and urinary markers in college football 
players (n = 98) in conjunction with intense exercise. Subjects (n = 54) 
ingested 15. 75 g·d- 1 of CrM for five days and an average of 5 g·d- 1 thereafter 
in 5 - 10 g·d- 1 doses for the remainder of the study. The effects of O - 6 
months (mean 4.4 ± 1.8 months, n = 12), 7 - 12 months (mean 9.3 ± 2.0 
months, n = 25), and 12 - 21 months (mean 19.3 ± 2.4 months, n = 17) were 
compared with subjects who did not take CrM (n = 44). No significant 
relationships were found among any of the groups for blood or urinary 
markers. Kreider et al. (2003) concluded that CrM supplementation (ofup to 
21 months) showed no adverse effects in the health status of college football 
players. 
Controlled studies of CrM supplementation have not shown any 
evidence of side effects (Vandenberghe et al., 1997; Benzi, 2000; Waldron 
et al., 2002). Therefore, causes other than CrM ingestion have been 
proposed, e.g., the co-ingestion of other supplements (Terjung et al., 2000), 
and problems associated with hydration and dietary problems (Schilling et 
al., 2001). 
The structure of Cr has both a positive and a negative charge and it is 
believed that the water retention is related to the additional water uptake 
when Cr ions enter the muscle. This increase within the cells can induce 
muscle oedema, cramps and other symptoms (Benzi, 2000). This is 
supported by other studies showing that muscle cramps are associated with 
hydration or dietary inconsistencies as increased total body water dilutes 
electrolytes, leading to cramps. Intracellular swelling has also been found to 
be one of the causes of muscle tightness and stiffness (Feldman, 1999). 
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Thus, it has been suggested that CrM should be administered only when 
properly hydrated and to avoid vigorous training during the primary stages 
of CrM ingestion (Benzi, 2000). This is very important, as the elderly are 
more at risk of dehydration due to a decreased fluid consumption rate and a 
reduced water content in the body (Davidhizar, Dunn & Hart, 2004 ). 
As the recognition and safe use of CrM increases researchers are 
starting to target possible uses for the supplement in a variety of disciplines 
such as treatment alternatives as well as the documented athletic 
improvements (Bemben et al., 2001). 
2.3 Supplementation for Athletes 
Differences in the performance of elite athletes, is often very small 
and any slight improvement in one's ability may change the outcome of the 
competition (Hopkins, Hawley & Burke, 1999). In order to achieve this 
additional gain, athletes are regularly in search of and consuming 
supplements that can potentially result in an ergogenic effect (Andres et al., 
1999). 
Creatine monohydrate is readily available for use in the international 
sporting community (Becque, Lochmann & Melrose, 2000). The athletic 
population willingly consumes CrM because of its perceived ability to 
increase muscular performance (Nelson, Arnall, Kokkonen, Day & Evans, 
2001). Athletes often take supplements to promote rapid increases in FFM, 
muscular strength and to accommodate extra training (Kreider et al., 1999; 
Brenner et al., 2003). 
A team of twenty five college football athletes (males aged 18 -
22 years) were studied by Bemben, Bemben, Loftiss and Knehans (2001a) 
over a period of nine weeks. 20 g·d- 1 of CrM or placebo was ingested for the 
first five days followed by 5 g·d- 1 for the remaining period. Along side the 
supplementation an RT program (4 d ·wk 1 ) was also implemented. On 
completion strength and power were improved in the Cr group in 
comparison to the placebo group, this was believed to be due to the increase 
in resynthesis of ATP and ADP (Bemben et al., 2001a). 
A study by Rico-Sanz and Marco (2000) found highly trained cyclists 
ingesting 20 g·d- 1 of CrM for five days increased both time to exhaustion 
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and oxygen consumption whilst performing three minute intervals of 30% 
and 90% maximal power output to the point of exhaustion. Grindstaff et al. 
( 1 997) performed a double-blinded randomised study on both male and 
female competitive swimmers. They were required to ingest 2 1  g·d- 1 of CrM 
or placebo for nine days. The findings found that not only did the subjects 
tolerate the CrM supplementation, but their sprint performance was also 
improved (Grindstaff et al. ,  1 997). 
Not all individuals, however, experience this improvement (Terjung et 
al. ,  2000). The data obtained from Biwer, Jensen, Schmidt and Watts (2003) 
revealed that soccer athletes ingesting 0.3 g·kt 1 ·d- 1 of CrM for six days did 
not experience any enhanced performance during a sub-maximal protocol 
combined with high-intensity intervals using a treadmill ergometer. 
Delecluse, Diels and Goris (2003) also found a negative response to 
CrM supplementation with nine highly trained sprinters. Following one 
week of CrM supplementation at a dose of 0.35 g·kg- 1 ·d- 1 ,  no ergogenic 
effects on single or repeated sprint times were observed even with varying 
rest periods. Delecluse et al. (2003) believe the negative response was due to 
the insufficient increase of intramuscular PCr and Cr content as a result of 
CrM supplementation and the fact that the subjects were highly trained 
athletes and had already trained their bodies to cope with vigorous training. 
2.4 Supplementation for Non-athletes 
Several authors have reported significant increases in LBM with CrM 
supplementation in younger subjects (Balsom et al. ,  1 993 ; Greenhaff, 
Bodin, Soderlund & Hultman, 1 994). Young subjects have been known to 
portray increases in LBM of about one - three kilograms and intra-muscular 
levels of PCr following supplementation have also been reported to improve 
by 1 5% (Rawson, Clarkson, Price & Miles, 2002). Volek et al. (2004) 
investigated the effects of short term CrM supplementation in conjunction 
with an RT program on performance, body composition and resting 
hormone concentrations. Seventeen males (aged 20.7 ± 1 .9) were randomly 
allocated to a supplementation (n = 9) or placebo (n = 8) group. 
Supplementation consisted of 0.3 g·kg- 1 ·d- 1 of CrM while both groups 
performed RT exercises 5 d·wk- 1 for four weeks followed by two weeks 
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reduction phase. They found that short term CrM supplementation was 
effective in maintaining muscular performance and body composition 
during the initial phase of RT however these changes were not related to the 
changes in hormone concentrations in the resting or the post absorptive state 
(Volek et al., 2004). 
Vandenberghe et al. (1997) examined the effects of CrM 
supplementation and RT on intramuscular PCr levels, muscular strength and 
body composition on sedentary females (n = 19) aged 19 - 22 years. The 
double blind study involved the females ingesting 20 g·d- 1 for four days of 
CrM or placebo followed by 5 g·d- 1 for ten weeks during which the RT 
program commenced (Vandenberghe et al., 1997). After the four loading 
days PCr levels increased 6% in the Cr group and during the low dose 
phase, muscular strength, body composition and muscular PCr levels all 
remained higher in the Cr group compared with the placebo group 
(Vandenberghe et al., 1997). 
In contrast, Bemben et al. (2001), also conducted a double blind study 
on sedentary males (n = 19) aged 18 - 25 years. Subjects ingested 20 g·d- 1 
of CrM or placebo for five days (loading phase) followed by 5 g·d- 1 for five 
days (maintenance phase) (Bemben et al., 2001). The study demonstrated no 
ergogenic effect of CrM supplementation in the untrained adult male but did 
indicate a possible advantage in increasing the endurance potential of larger 
muscle groups (Bemben et al., 2001). 
Smith et al. (1998) studied age and the differences in CrM 
supplementation on muscle metabolism. They found that CrM 
supplementation of 0.3 g·kg- 1 ·d- 1 for five days had a greater influence with 
middle-aged (>50 years) individuals than younger (<40 years) subjects 
(Smith et al., 1998). After performing single leg knee extension the results 
indicated that CrM supplementation enhanced muscular endurance in both 
groups, however, muscle PCr availability, hydrolysis and resynthesis was 
greatly improved in the middle-aged individual (Smith et al., 1998). 
2.4.1 Elderly 
Mature populations experience a loss of muscular strength after the 
age of 50, accelerating at the age of 70 years and above (Aniansson, 
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Hedberg, Henning & Grimby, 1986). This loss can be attributed to muscle 
atrophy, as a result of reduced TCr levels, a sedentary lifestyle, a decline in 
muscle force-generation as well as impaired neurological function and 
mobility (Aniansson et al., 1986; Fiatarone et al., 1994; Bassey, 2002; 
Degens & Alway, 2003). It has been reported that approximately 0.5 
kilograms of muscle is lost per annum in adults that do not perform regular 
exercise and a further 50% loss of type II muscle fibres in adults over the 
age of 80 years (Elliott, Sale & Cable, 2002). It has also been reported in the 
elderly that there is a 2.5% and 2% annual loss of strength for knee flexion 
and knee extension (Frontera et al., 2000). 
This loss of muscle size and strength as well as changes in the 
sarcoplasmic reticulum and motor neurons contribute to a decreased ability 
to perform daily activities (Frontera et al., 2000). Decreases in the functional 
ability of the respiratory, cardiovascular and neuromuscular systems further 
result to this decrease in strength and aerobic power (Izquierdo et al., 2003). 
Aging is also associated with a decrease in FFM, a reduced metabolic rate 
and a lower capillary to fibre ratio (Campbell et al., 1999; Laguno, Miro, 
Perea, Picon & al., 2002), this loss of muscle is normally replaced with 
connective and fatty tissues contributing to various age related disorders 
(Ferri et al., 2003). 
Rawson and Clarkson (2000) found that elderly people have lower 
intra-muscular TCr concentrations. Elderly individuals have also been 
reported to experience a greater increase in muscle Cr and PCr, and PCr 
re-synthesis due to CrM supplementation compared with healthy subjects 
(Rawson & Clarkson, 2000). The reduced TCr concentration, due to a lower 
Cr uptake in the muscles, could also contribute to the decrease seen in type 
II muscle fibres (Bermon et al., 1998). 
Chrusch et al. (2001) performed a CrM supplementation experiment, 
using a double-blinded placebo design with thirty-three men aged 60 - 84 
years old over twelve-weeks. A CrM loading phase of five days at a dosage 
of 3 g·ki 1 ·d- 1 of body weight, followed by a maintenance phase of 
0.07 g·kg- 1 ·d- 1 of body weight thereafter, resulted in enhanced muscular 
strength, endurance and power of the lower body as well as LBM (Chrusch 
et al., 2001). 
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Chrusch et al. (2001) found that PCr availability was an important 
factor for preventing fatigue during exercise. The men were able to train at 
higher volumes (31 % higher than initial volumes) as a result of both the 
training program and CrM supplementation (Chrusch et al., 2001). Rawson, 
Wehnert and Clarkson (1999) also performed a double-blinded placebo 
experiment involving elderly males aged 60 - 78 years old and found that 
their results also supported the notion that CrM supplementation and RT 
allows for a greater improvement of strength performance. 
In contrast to these findings, Eijnde et al. (2003) investigated the 
effects of CrM supplementation and exercise on males (n = 46) aged 
between 55 and 75 years old. The Cr group were instructed to ingest 5 g·d- 1 
of CrM while both groups performed two - three sessions per week of 
moderate RT and cardio-respiratory endurance training for six months. They 
concluded that long term CrM supplementation and RT did not improve the 
physical fitness of males aged 55 to 75 years old (Eijnde et al., 2003). 
Rawson, Clarkson, Price and Miles (2002) found that CrM ingestion 
in older subjects had no effect on intra-muscular PCr levels, also that elderly 
subjects had significantly higher blood Cr and muscle PCr levels initially 
when compared with younger adults. Bermon, Venembre, Sachet, Valour 
and Dolisi (1998), also found that CrM supplementation failed to show any 
ergogenic effects towards dynamic strength or isometric endurance 
performances in sedentary elderly men and women following an eight week 
training program. They also demonstrated that CrM ingestion did not extend 
the time to fatigue nor did it induce additional strength gains in the latter 
stages of exercise. These contradictions could possibly be due to a poor RT 
program design and/or insufficient supplement levels (Bermon et al., 1998). 
There are many potential reasons as to why CrM appears to have no 
ergogenic effect in older individuals. Elderly people are believed to have a 
decreased Cr absorption rate in the gut, slow transport in the blood, and 
inappropriate rate of Cr uptake into muscles after supplementation (Rawson 
et al., 2002). To obtain similar performance increases to younger 
individuals, older individuals require a longer supplementation period or a 
higher CrM supplement dosage (Rawson & Clarkson, 2000). 
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2.5 Myopathy 
Idiopathic inflammatory myopathies was first documented in three 
patients by Wagner and Unverricht in 1887 (Bronner, Linssen, van der 
Meulen, Hoogendijk & de Visser, 2004). At first the three cases were 
termed PM, after realising the occurrence of cutaneous irregularity together 
with the disease, Unverricht changed the name to DM a few years later 
(Hashmat & Daud, 2004 ). After this discovery the terms PM and DM were 
loosely used and over many decades it was alleged the dermatological 
irritation was a part of the disease. The status of PM remained vague until 
the late 201h century where Walton and Adams started to classify the 
symptoms in 1958. This was later completed in 1975 by Bohan and Peter 
who documented the well known diagnostic criteria for PM and DM that are 
still used today (Callen, 2002; Bronner et al., 2004). Diagnosis included ( 1 )  
a symmetrical weakening of  the limb girdle muscles declining over several 
weeks even months, (2) elevated CK levels, (3) electromyographic triad, 
muscle response to nerve stimulation, of small amplitude, short duration 
polyphasic motor unit action potentials, positive Harp waves and increased 
insertional irritability and impulsive high frequency discharges and ( 4) 
muscle biopsy abnormalities (i.e. necrosis, phagocytosis, perifascular 
atrophy, interstitial infiltrates of mononuclear cells and degeneration and 
regeneration) (Launay et al., 2001 ;  Cleland & Venzke, 2003). The skin 
rashes according to Bohan and Peter ( 1975) were the only distinguishing 
feature between PM and DM. In 1991,  Dalakas refined the diagnostic 
foundation that Bohan and Peter provided by including specific 
histopathological abnormalities in its description (Bronner et al., 2004 ). 
2.5. 1 Polymyositis 
Polymyositis 1s a cell-mediated autoimmune disorder, the 
abnormalities begin with a group of cells called lymphocytes, known as 
CD8+ T-lymphocytes (Dalakas, 2001 ;  Hilton-Jones, 2003; Komiya et al., 
2004). These lymphocytes continuously migrate back and forth between the 
bloodstream and peripheral tissue. In healthy individuals, lymphocytes act 
as a defence mechanism against invading pathogens, bacteria and viruses, or 
24 
against abnormal body cells and cancerous cells, by physically attacking or 
using chemical discharges to attack the foreign agents (Martini, 1998). 
In patients with PM, CD8+ T-lymphocytes and reactive macrophages 
surround, invade and destroy normal muscle fibres which express Major 
Histocompatibility Complex class I antigens, also known as Human 
Leukocyte Antigen, as though they were foreign or abnormal to the body 
(Buchbinder, Forbes, Hall, Dennett & Giles, 2001; Hara et al., 2003; Vianna 
et al., 2004). Other cells start to aid lymphocytes by producing antibodies to 
attack the tissue, these misguided antibodies are referred to as 
autoantibodies, causing architectural and functional damage, known as auto­
immunity (Martini, 1998), resulting in the loss of cross-striations in targeted 
muscle fibres (Buchbinder et al., 2001). 
Diagnosis of DM can be made through electromyography and 
serological data, however the "gold standard" for diagnosis is through 
muscle biopsy samples (Cleland & Venzke, 2003). Due to the disease 
muscle membranes start degenerating and releasing muscle enzymes from 
the muscle fibre. Creatine phosphokinase, muscle enzyme, can be found in 
significantly high concentrations above normal levels. Due to muscle 
damage, changes can also be found with low amplitude short acting firing 
potential and fibrillations (Cleland & Venzke, 2003). Muscle biopsies taken 
in the study by de Oliveira Kamikowski, Costa, Osella and de Toledo 
Nobrega (2002) of the biceps brachii and quadriceps muscles from a PM 
patient showed a degeneration and disorganisation of striated muscle fibres. 
High counts of endomysial infiltrates of polymorphonuclear cells were also 
found with rare signs of regeneration, phagocytosis and endomysial fibrosis 
throughout the muscle. Examples of this can be seen in Figure 1 from 
Hashmat and Daud (2004). 
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a .) b.) 
Figure I .  PM. a.) Muscle biopsy showing an infiltration of inflammatory 
cel ls within the muscle . b . )  A longitudinal view of the inflammatory 
infiltrate within a muscle sample (Hashmat & Daud, 2004) . 
As well as the degeneration of muscular tissue PM involves persistent 
inflammation (Dalakas, 200 1 ) . Muscle weakness is usually symmetrical and 
develops slowly over a few months, even years (Lampa et al . ,  200 1 ) . Early 
signs of PM include difficulty rising from a chair, cl imbing a flight of stairs, 
self grooming or lifting the arms above head level (Hilton-Jones, 2003) .  
Other symptoms include : weight loss, pain, fatigue, shortness of breath, 
fever, tenderness within the muscle, skin changes, arthritis (Wortmann, 
2002), frequent gastrointestinal , pulmonary and cardiac dysfunction (Joffe et 
al . ,  1 993) . Difficulty in swallowing, dysphagia, and chocking incidents are 
very common, affecting more than 60% of patients especially in the later 
stages of the disease (Dalakas, 200 1 ) . 
Diagnosis is normally based upon the presence of proximal muscle 
weakness, an increase in serum levels  of enzymes derived from skeletal 
muscle, abnormal electromyography and the presence of an inflammatory 
infiltrate in muscle biopsy (Brouwer et al . ,  200 1 ;  Belostocki & Paget, 2002). 
These diagnostic measures should be cautiously examined as serum enzyme 
levels such as CK are influenced by many factors such as race, prior 
exercise performed, fitness levels, disease activity and general physical 
activity (Chung et al . ,  2003) .  Electromyography abnormalities differ 
between individuals and in more than 20% of cases can show no 
abnormalities, as affected muscles can contain areas of normal muscle 
(Chung et al . ,  2003) .  
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2.5.2 Dermatomyositis 
Dermatomyositis is believed to be due to a number of incidences ( 1 )  
the binding of antibodies to microvascular components, (2) damage of the 
complement C5b - C9 membrane and (3) the opening of the classic 
complement pathway. The activation of this pathway results in the loss of 
capillaries and ischemia-induced damage of muscle fibres with 
inflammatory infiltrates (Hara et al. ,  2003; Komiya et al., 2004). Diagnosis 
of DM is similar to that of PM in reference to muscular responses to the 
disease however DM is actually quite different from PM. Dermatomyositis 
is a humorally mediated auto-immune disorder (Hilton-Jones, 2003). It 
involves the presence of a distinctive skin rash on the eyelids, cheeks and 
hands as well as a flat red rash on the knees, chest, neck and back (Dalakas, 
200 1 ;  Figarella-Branger et al., 2003) seen Figure 2 by Callen (2002). The 
major feature of DM is the saturation of inflammatory cells into the 
perivascular and interstitial regions surrounding the myofibrils (Dalakas, 
2001) .  Dermatomyositis is also characterised by vasculopathy, disease of 
the blood vessels, and the deposition of membrane attack complexes (Hara 
et al . , 2003; Komiya et al. ,  2004). 
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a.) 
c .) 
b .) 
d.) 
Figure 2. DM. a .) Juvenile type DM portraying a large infiltrate of 
inflammatory cells within the perimysium. b.) Adult DM characterised by a 
group of degenerative fibres within a fascicle (Figarella-Branger et al . ,  2003) 
c.) The typical rash associated with DM. d .)  Lesions on the hand of a patient 
with DM (Callen, 2002) . 
Dermatomyositis is also characterised by a form of capillaropathy 
(loss of capillaries numbers), muscle hypoxia, muscle fibre death and 
perifascicular myofibril atrophy (Dalakas et al . ,  1 993 ; Hilton-Jones, 2003) .  
The activation of the complement system i s  believed to  be  the sole cause of 
capillary depletion, one of the initial signs of the disease seen in muscle 
biopsies (Kamiya et al . ,  2004) . Another uniqueness to DM is the association 
of malignancies with the disease (Dalakas , 200 1 )  however this is not 
observed in Juvenile DM (JDM) (Figarella-Branger et al . ,  2003) .  
Dermatomyositis is a disease also found in  children. Lymphocytes and 
macrophages invade and destroy capillaries in JDM as it does in adult DM, 
shown by Figarella-Branger, Civatte, Bartoli and Pellissier (2003) in Figure 
2, however JDM does differ (Rider et al . ,  2002) . Subcutaneous 
calcifications are more common in JDM, muscular weakness is not seen as 
much, the emotional state of the child is usually affected, the face tends to 
look flushed, the rash is not always as visible and the bowel may become 
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involved. On the other hand distal weakness can occur in adult DM. Adult 
DM also progresses slowly over several weeks and in severe cases can 
include respiratory failure (Hilton-Jones, 2003). 
2.5.3 Treatment and Prevention 
The prospects of a patient with any form of IM is reliant on the early 
identification and treatment (Vencovsky et al., 2000). The effective 
treatment of PM and DM comprises immunosuppressive and 
immunomodulating agents, these current therapies are generally identical 
for all IIM's (Choy & Isenberg, 2002). Prednisone or its primary metabolite 
Prednisolone, an immunosuppressant, has been found to be an effective first 
line treatment for many patients (Cleland & Venzke, 2003). Patients start 
with a high oral dose of Prednisone or Prednisolone daily for four to six 
weeks until there is an improvement in symptoms and a decrease in the 
serum CK levels. The dose is tapered down to a maintenance dosage with 
improvements, which is continued for at least twelve months (Mastaglia, 
Phillips & Zilko, 1999). 
Most medical practitioners use steroids as a first line treatment as 
most believe it improves the disease among the majority of patients (Choy 
& Isenberg, 2002). However, steroids have been associated with the 
re-appearance and morbidity of certain diseases (Danieli et al., 2002). About 
32% to 41 % of patients also suffer from increased disability as well as other 
various side effects as a result of steroids and with long term prescription of 
the drug, osteonecrosis and osteoporotic vertebral fractures are common 
(Lundberg & Chung, 2000; Dalakas, 2001; Choy & Isenberg, 2002). 
Therefore non-steroidal immunosuppressants, such as Azathioprine and 
Methotrexate, are more commonly prescribed (Mastaglia et al., 1999; 
Vencovsky et al., 2000). 
Azathioprine is commonly used as the preferred steroid-sparing agent 
in PM and DM (Choy & Isenberg, 2002). It can be slow acting, however it 
is still popular as it is suggested to allow for a lower dose of Prednisone or 
Prednisolone with time (Hilton-Jones, 2003). Oral Methotrexate is a second­
line treatment most commonly used for patients with rheumatoid arthritis. It 
was first reportedly used in the treatment of childhood and adult DM, as it is 
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known to suppress inflammation and improve function. However, 
Methotrexate has also been associated with side-effects such as pulmonary 
and liver dysfunction, haematological disorders and hair loss requiring 
regular blood tests to monitor progression (Choy & Isenberg, 2002; Cleland 
& Venzke, 2003). 
Intravenous immunoglobulin (IVIg) therapy is effective for patients 
who do not respond well to Prednisone or Prednisolone. Intravenous 
immunoglobulin therapy is the last drug treatment administered and it is 
believed to be effective for patients who suffer from severe flares of the 
disease and whose conditions are declining (Mastaglia et al., 1999; Danieli 
et al., 2002). 
Dermatomyositis responds to these therapies more positively than PM. 
Most patients make a full recovery back to initial strength, which is 
sustained by maintenance doses of the treatments (Dalakas, 2001). A study 
by Dalakas et al. (1993) found that IVIg therapy enhanced muscular strength 
in patients with DM, cleared the rash, restored the capillary network and 
improved the structure and function of tissues in muscle biopsies. However, 
the effectiveness of IVIg is usually short-lived as repeated treatments are 
needed for long term results and the drug is very expensive to obtain 
(Dalakas et al., 1993). 
2.5.4 Problems Associated with Current Drug Therapies 
In some cases of PM and DM, patients can continue to demonstrate 
reduced muscular strength despite the disappearance of inflammation due to 
the disease or in extreme cases even intense treatment of IVIg (Lundberg & 
Chung, 2000). There are a number of factors that can describe an 
individuals' poor response to these drug therapies, including the duration of 
muscular weakness prior to diagnosis, the severity of the weakness and an 
individuals association with malignancy or cardiac disease (Joffe et al., 
1993). Also the duration of treatment and inadequate dose prescribed can 
also affect ones response to particular treatments (Hilton-Jones, 2003). It 
can take several weeks for mixed treatments like corticosteroid and 
immunosuppressive treatment to have an effect therefore early treatment is 
essential (Vencovsky et al., 2000). 
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A decrease in CK concentrations normally is associated with 
increased strength, however, with many immunosuppressive treatments a 
decrease in CK concentration does not always mean an increase in muscular 
strength (Dalakas, 2001). A reason for this is that patients who have been 
suffering with the IM for a long period have noticeably less muscle fibres 
due to atrophy than those patients recently diagnosed. In contrast CK levels 
can be promoted by some medications, like Methotrexate, as well as trauma 
and unaccustomed exercise (Komiya et al., 2004). Furthermore, as there is 
strict criteria for identifying PM (Rosenkranz, 2002) the clinical diagnosis 
of PM can vary between General Practitioners. Another factor is age, as 
elderly patients have a less favourable response to drug therapy when 
compared with younger patients (Belostocki & Paget, 2002). 
The same fate seen in the elderly population is common in the patient 
population. They are both associated with reduced intra-muscular ATP, Cr 
and PCr (Wiroth et al., 2001). Multiple studies by Tarnopolsky and others 
(1997; 1999; 1999; 2001) when investigating numerous diseases including 
IIM, found significantly lower PCr concentrations for all patients when 
compared with normal controls. It has been reported that the amount of TCr 
is 14% lower for patients with IIM (Tamopolsky & Beal, 2001). 
2.5.5 Natural Therapies 
Tamopolsky and Martin (1999) demonstrated that a ten-day CrM 
supplementation program could significantly increase strength and LBM in 
patients with a variety of neuromuscular diseases. Studies by Tamopolsky 
and Parise (1999) have found that short-term (fourteen days) CrM 
supplementation can increase PCr concentrations by 15% to 20% in both 
healthy humans and patients with myopathies. They have also found that 
individuals with the lowest initial muscle PCr concentrations show the 
greatest increase in response to CrM supplementation. Tamopolsky and 
Martin (1999), suggest that the possible mechanisms responsible for the 
increased LBM and strength is possibly due to a significant increase in PCr 
content, allowing for an increased training volume and increases in protein 
synthesis. 
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Although most studies suggest a beneficial effect of CrM 
supplementation there are a few studies that show no ergogenic effect. One 
such study is by Tamopolsky, Roy and MacDonald ( 1 997), yet they support 
CrM use for patients with mitochondrial cytopathies even though their 
results do not support it. They found that CrM ingestion had a slight effect 
on high-intensity anaerobic and aerobic performance but did not affect body 
composition, aerobic cycle ergometry performance or the ability to complete 
daily activities (Tamopolsky et al. ,  1 997). 
In addition to these findings V orgerd et al. (2002) found CrM 
supplementation to be detrimental to patients with McArdle Disease, one of 
the most common metabolic myopathies. It was previously reported that 
short-term low doses of CrM supplementation (60 mg·ki 1 ·d- 1 ) had positive 
effects such as increasing the exercise capacity of patients. In the study by 
Vorgerd et al. (2002) a higher dose of CrM ( 1 50 mg·ki 1 ·d- 1 ) was ingested 
during a double-blinded placebo controlled trial. The dose actually 
worsened the clinical symptoms of exercise intolerance despite the positive 
neurophysiological findings (Vorgerd et al. , 2002). 
However, the reductions in muscle Cr and PCr in patients with 
neuromuscular disorders provide theoretical support for the use of CrM as a 
therapeutic intervention. Strength training in conjunction with the CrM 
ingestion may also provide further benefits, possibly delaying the onset of 
muscle weakness and atrophy (Spector et al. ,  1 997). 
2.6 Exercise 
When the blood flow is restricted, the availability of Cr for active 
muscles to absorb is also reduced. Due to this reduction, there is a further 
decrease in ATP availability and PCr re-synthesis, as this process is oxygen 
dependant, reducing the contractile force of each muscle (Urbanski et al., 
1 999; Yquel et al. , 2002). Previous research by Harris et al. ( 1 992) have 
found that exercise promotes blood flow to the active skeletal muscles, thus 
increasing the amount of available Cr and ATP and restoring PCr re­
synthesis. 
Exercise has numerous health benefits. Apart from cardiovascular 
improvements exercise has been known to improve and maintain physical 
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performance, hindering the unavoidable loss of muscle mass and 
neurological function found with aging (Bennell et al., 1997; Bassey, 2002; 
Elliott et al., 2002). This gain in muscular strength and mass is thought to be 
the result of neural adaptations and muscle hypertrophy (Kreider et al., 
1999; Augustsson et al., 2003). 
2.6.1 Adaptations to Exercise 
As a result of exercise, adaptations can be seen in muscles as a result of 
structural, neural and mechanical changes (Abernethy & Jurimae, 1996). 
Muscle hypertrophy is the result of an increase in individual muscle fibre, 
whole muscle cross-sectional area and possibly hyperplasia, the abnormal 
increase of normal cells in tissue (Chesnut & Docherty, 1999). Higbie, 
Cureton, Warren and Prior (1996) illustrated that after heavy RT changes in 
strength were not only due to hypertrophy but also to increased neural 
activation within the muscle. 
Changes in the recruitment of muscle fibres, discharge frequency and 
synchronisation of the motor unit, as well as reflex responses, increased 
excitability of the alpha motoneurone pool and/or motor end plates, a 
decrease in Golgi tendon organ inhibition and in the activation of the 
antagonistic muscles have all been suggested as possible neural adaptations 
to heavy resistance exercise (Staron et al., 1994 ). Although muscle fibre 
characteristics are determined to a large extent by genetics, training the 
recruitment process can enhance the synchronisation of muscle fibre 
discharge frequencies (McLaughlin, 2001 ). It has also been suggested that 
training creates new neural pathways, increasing the neural flow to motor 
neurons in turn increasing the activation of muscle groups involved in the 
contraction (Evetovich et al., 2001). 
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Neural adaptations have also been proposed as the main principle for 
any increase in performance seen in the first few weeks of resistance 
exercise (Staron et al., 1994; Evetovich et al., 2001 ). However it has become 
increasingly more aware that intramuscular changes are also evident during 
this period (Staron et al., 1994). After six weeks of training muscle 
hypertrophy, an increase in cross-sectional area of the muscle being 
employed, mainly contributes to the strength increases (Chesnut & Docherty, 
1999). 
Earlier work by Staron et al. (1991) and Staron and Johnson (1993) 
show significant hypertrophy in all major muscle fibre types (I, Ila and llb) 
as well as the fibre type conversions between type llb and Ila. Increases of 
15.6%, 17.3% and 28% for the fibre types I, Ila and llb were seen in the 
vastus lateralis muscle of females after six weeks of high intensity RT, as 
well as a significant decrease in type llb fibres (pre 24.9%; post 6.7%) 
(Staron et al., 1991). Larger increases of 15%, 45% and 57% for the muscle 
fibre types I, Ila and llb were demonstrated in the vastus lateralis muscle of 
females after 20 weeks of high intensity RT (Staron & Johnson, 1993). 
It is still not known to what extent this remodelling of intramuscular 
structure has on strength, however gradual increases in the number and/or 
size of the myofibrils as well as the decrease of Ila fibres to the conversion 
to llb has been postulated to contribute to these strength increases (Staron et 
al., 1 994). The study by Chestnut and Docherty (1999) states that untrained 
subjects adapt more generically to exercise than trained subjects. Therefore 
neural changes can also be seen with light resistance exercise performed on 
sedentary individuals. 
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2.6.2 Contralateral Limb 
Several authors have reported contralateral strength increases due to 
unilateral exercises (Housh, Housh, Weir & Weir, 1996; Evetovich et al., 
2001; Munn, Herbert & Gandevia, 2004; Munn, Herbert, Hancock & 
Gandevia, 2005) where as others have reported no strength changes (Narici, 
Roi, Landoni, Minetti & Cerretelli, 1989; Garfinkel & Cafarelli, 1992; 
Housh, Housh, Johnson & Chu, 1992). The latest review of existing studies 
showed that the untrained limb produces a small yet statistically significant 
increase of up to 8% from initial strength due to unilateral training (Munn et 
al., 2005). 
Narici, Roi, Landoni, Minetti and Cerrettelli (1989) and a study by 
Krotkeiwski et al. (1979) (cited in Housh et al., 1992) examined the effects 
of unilateral training on the cross section area of the contralateral limb using 
various techniques, neither found a cross-training effect in relation to 
hypertrophy. Housh, Housh, Johnson and Chu (1992) study was also 
consistent with these findings, however, although no significance was 
reported (p> 0.0008) increases in cross sectional area of the contralateral 
muscles increased (0.1 to 14.0%) as well as PT measurements (6.7 to 14.8%) 
of the contralateral side of the body during testing. Munn, Herbert, Hancock 
and Gandevia (2005) revealed a significant relationship between strength 
gains for the trained and untrained limbs. However, the circumference 
measures of the tested upper limb may have been too impervious to detect 
any changes in cross sectional area, Munn et al. (2005) stated that it was 
unlikely to be caused by muscle hypertrophy. 
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The mechanisms behind the increase in contralateral strength remains 
unclear (Munn et al., 2004). Two possible mechanisms for the explanation of 
the cross-training effect have been proposed 1 )  motor impulses circulating to 
the contralateral side of the body and 2) contraction of the contralateral side 
of the body in an effort to maintain stability and assume the appropriate 
posture for the unilateral testing (Housh et al. , 1 992; Evetovich et al., 200 1 ) . 
It has also been suggested that a learning effect following unilateral RT may 
cause increased strength results in the contralateral limb due to the activation 
of both the contralateral and ipsilateral sensorimotor cortex (Munn et al., 
2005). In the absence of muscle hypertrophy an increased ability to recruit 
motor units and the firing rate of these units through central neural 
mechanisms may be part responsible for the increases in strength as well as 
other neural changes involving spinal and supraspinal pre-motor networks 
has also been proposed (Munn et al. , 2005). 
It is believed that with a longer training period or a greater magnitude 
of strength gained in the trained limb, statistically significant increases in 
strength and cross sectional area of the contralateral side could be recorded 
(Housh et al., 1 992; Munn et al. ,  2005). Since training volume, duration and 
training speed are thought to have an effect on the degree of strength 
adaptations seen in the trained limb, it is probable that they could also 
influence changes in the contralateral limb (Munn et al., 2005). 
2.6.3 Therapeutic Exercise 
The benefits of exercise for health related purposes are now widely 
accepted as a means of rehabilitation and as this is applicable across all ages 
its popularity has excelled (Bassey, 2002). The therapeutic value of exercise 
training in the enhancement of muscular strength and muscle mass has been 
well documented for healthy and elderly individuals (Tracey et al., 1 999). A 
study by Ferri et al. (2003) supports the use of exercise with elderly patients 
over the age of 65 years as it was found to increase strength and power, in 
addition to producing further gains in performing daily activities. Rhodes et 
al. (2000) investigated the effects of one-year progressive RT in forty four 
elderly women (mean age 68.8 years). The study proved beneficial as 
significant changes were found in muscle strength for the bench press 
(> 29% ), bilateral leg press (> 1 9%) and unilateral leg press (> 20%) as well as 
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improvements in biceps curl, triceps extension and quadriceps extension. 
The overall strength increases over the one-year period ranged from 19 -
53%. These changes also found associated increases to bone density in 
lumbar and femoral regions (Rhodes et al., 2000). 
No recent published data supports rest or the use of restricted exercise 
for the rehabilitation of patients with PM and DM. There is some positive 
evidence, supporting exercise training as beneficial for patients with various 
neuromuscular disorders (Alexanderson et al., 1999; Alexanderson, 
Stenstrom, Jenner & Lundberg, 2000; Cleland & Venzke, 2003). It is often 
believed that the use of an exercise regime for a person with various 
inflammatory myopathies is dangerous because exercise, mainly eccentric, 
can cause increases in CK levels and muscle fibre inflammation, which can 
induce muscle fibre death. It has previously been reported that even after 
five days of exercise, cytokine levels are high which can result in muscle 
fibre damage (Spector et al., 1997). Furthermore exercise induces 
lymphocytes and neutrophils migration and increases the number of killer 
T-cells and cytotoxic T-cells that result in further inflammation (Spector et 
al., 1997). 
However, Mastaglia, Phillips and Zilko (1999) suggested that exercise 
can improve muscular strength in patients with PM and DM when 
prescribed appropriately. A study conducted by Spector et al. (1997) 
showed that a twelve-week high-resistance strength training program 
significantly improved dynamic muscle strength without any evidence of 
muscle damage in patients with IBM. DeBolt and McCubbin (2004) 
examined the effects of an eight week home-based RT program on balance, 
power, and mobility in adults with multiple sclerosis. Twenty-nine women 
(age, 50.3 ± 8.5 years) and eight men (age, 51.1 ± 7.1 years) were randomly 
assigned into an exercise (n = 19) and a control (n = 17) group. The control 
group maintained their exercise levels while the exercise group performed 
three sessions of lower extremity exercises a week. Although measurements 
of balance and mobility did not significantly change a significant 
improvement in leg extensor power (an increase of 30%) was seen. The 
home-based program was tolerated well by the individuals as it did not 
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cause any additional injuries or enhance any of the symptoms as a result of 
the disease (DeBolt & McCubbin, 2004 ). 
Wiesinger et al. (1998) performed a training program for six months 
on a group of eight patients suffering from either PM or DM. Their results 
were compared with a group of five patients that also suffered from the 
disease that did not undergo the training. The long term physical training did 
not result in any significant increases in disease activity and it improved 
both the patients' muscular strength and cardiorespiratory fitness (Wiesinger 
et al., 1998). 
After twelve-weeks of moderate exercise, a study by Alexanderson, 
Stenstrom and Lundberg (1999) also found no signs of increased disease 
activity in a group of ten PM adults aged 27 - 60 years. Upon completing 
the whole body exercise regimen every patient showed improvements in 
muscle function of the upper and lower limbs as a result their medication 
was reduced (Alexanderson et al., 1999). 
The same exercise program was employed again in eleven patients 
with PM and DM. These patients were aged between 23 - 80 years old and 
were recently diagnosed with IM. After twelve-weeks of exercise training 
no signs of increased inflammation were detected and significant 
improvements in muscle function and quality of life were also evident 
(Alexanderson et al., 2000). 
Amardottir, Alexanderson and Lundberg (2003) performed a twelve­
week home-based training programme adapted from Spector et al. (1997) 
with seven IBM patients ( aged between 45 - 78 years old) with an 
additional 20 minutes walk or a five minutes stationary cycle five days a 
week. No signs of increased inflammation were found and the home-based 
training program was well tolerated with all except one experiencing 
improved muscle function (Amardottir et al., 2003). 
Exercise is very important in that not only does it maintain the 
remaining strength, but also aids the muscles' recovery following damage 
due to the inflammatory process (Hilton-Jones, 2003). Exercise may also 
help reverse or to some extent prevent the side effects of steroid myopathy 
(Mastaglia, Garlepp, Phillips & Zilko, 2003). 
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It is unclear as to when the optimal time is to introduce exercise as a 
form of therapy, however it is recommended that patients are gradually 
eased into physical activity as their disease subsides (Lundberg & Chung, 
2000). The patients' current physical ability and disease status should 
determine the balance between physical exercise and rest (Cleland & 
Venzke, 2003). It has been suggested that the exercise should be in the form 
of a light to moderate home-based exercise program for the whole body or a 
low intensity aerobic program on a bicycle or in a pool (Lundberg & Chung, 
2000). Both passive and active exercise has been suggested to improve 
muscular performance as well as reduce the risk of developing contractures 
(Hilton-Jones, 2003 ). It is also recommended that the training consist 
mainly of concentric muscle contractions due. to the ultra structural damage 
resulting from eccentric muscle contractions (Wiesinger et al., 1998). 
Creatine kinase levels should therefore be used as a guide for the exercise 
program as it is an indicator of the sensitivity of the disease (Cleland & 
Venzke, 2003). 
2. 7 Implications of the Literature Review 
There are a large number of studies investigating different training 
regimens and their role in increasing muscular strength and mass in a variety 
of populations (Folland, Irish, Roberts, Tarr & Jones, 2002). However, there 
is little experimental evidence documenting beneficial effects of exercise in 
patient populations suffering from PM and DM and even less incorporating 
CrM supplementation into the program. There are also limited studies 
examining the effects of exercise on the non-trained limbs (Evetovich et al., 
2001 ). This investigation is the first study to incorporate contralateral 
findings in this particular patient population. 
This study was therefore designed to examine the effects of a twelve­
week home-based exercise program and CrM supplementation on trained 
and untrained limbs in patients with PM and DM. It is hypothesised that 
training and supplementation will lead to an increase in muscular mass and 
strength for each individual involved in the study. 
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CHAPTER THREE 
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3.1 Subjects 
3. MATERIALS AND METHODS 
The participants in the study were recruited from the Neuromuscular 
Clinic within the Australian Neuromuscular Research Institute at Sir Charles 
of Gairdner Hospital (SCGH). The study targeted patients with PM or DM 
between the ages of 20 and 60 years due to the low numbers of patients 
available. A group with similar demographics to the patients were also 
recruited from the local community (see Appendix A). Edith Cowan 
University (ECU) Ethics Committee and SCGH Human Research Ethics 
Committee both approved the study. 
Ten subjects (3 = patients, 7 = controls) participated in the study. 
However, one patient withdrew due to the disease flaring as a result of a 
cold after the loading phase and one control withdrew after the 5th week due 
to time restrictions and nausea as a result of the supplementation. The two 
patients ( one = male, one = female) that completed the study were matched 
with two controls of the same gender and similar physical characteristics. 
The male patient (197 cm, 81 kg) aged 24 years was matched with a control 
(197 cm, 78 kg) aged 20 years. The female patient (159 cm, 101 kg) aged 42 
years was matched with another female (158 cm, 79 kg) aged 41. The 
patient that withdrew after the second week (164 cm, 54.5 kg) aged 60 years 
was matched with a female control (155 cm, 58 kg) aged 51 years who 
completed the study. 
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Patient One was a 24-year-old male student who was diagnosed with 
DM in December 2001. Prior to diagnosis, he was a fulltime student and 
exercised regularly, swimming at a state level when younger. Six weeks 
prior to diagnosis, he was bed bound. Tests showed a history of pulmonary 
infiltrates whilst physical tests showed severe muscle weakening in the left 
vastus lateralis and joint stiffness. He began taking Methotrexate (10 
mg·wk- 1) and Prednisolone (50 mg·d-1). Prednisolone was dropped 4 months 
later to 7. 5 mg·d- 1 , this was not well tolerated and both Methotrexate and 
Prednisolone were increased to 20 mg. During this time a distinct rash 
started to appear and Plaquenil (400 mg·d- 1 ) was introduced shortly after. In 
the first eight months the muscle disease was mildly active and Imuran (150 
mg·d- 1) was also prescribed. Within the year, after no relapse, he started to 
stabilise and began tapering off the medications. 
Patient Two was a 43-year-old woman whom began displaying 
symptoms of PM in early 1999 when she was three months postpartum. 
Tests showed increased activity within myelinated fibres consistent with 
early active IM. The onset of PM was thought to be triggered by an episode 
of fever and malaise. The fever eventually passed but the malaise continued 
to a certain degree. By April 2000 she complained of increased muscle 
aching in the thigh and weakness in the shoulder and hip girdles. A month 
later she recorded an elevated CK reading and was prescribed 75 mg·d- 1 of 
Prednisolone, only to relapse resulting in the addition of Methotrexate 
(15 mg·wk-1). A case of erythema, possibly induced by steroids was seen in 
January 2001. A bone density scan in June showed femoral osteopaenia, 
there was also evidence of patellofemoral osteoarthritis in both knees, the 
left being the worst affected. By April she was taking Prednisolone 
(50 mg·d-1), Methotrexate (20 mg·wk- 1 ) and Imuran (150 mg·d- 1 ) from 
which the disease started to stabilise and Prednisolone was slowly dropped. 
The characteristics of all 10 subjects can be seen in Table 1. 
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Table 1. 
Characteristics for the Study Participants 
Age Height Weight Weight 
(yrs) (cm) (kg) (kg) 
Group (pre) (post) 
Control 
Male (n = 3) 43.7 ± 1 83 ± 77.9 ± 77.5 ± 
2 1.2 12. 1  7.2 I 1 1.2**  
Female (n = 4) 42.8 ± 1 62.8 ± 68.4 ± 69.3 ± 
7. 1 8.0 9.0 8.2 
Total (n = 7) 43. 1 ± 1 7 1 .4 ± 72.5 ± 72.0 ± 
1 3.3 1 4. 1  9. 1 9. 1 ** 
Patient 
Male (n = 1 )  24.0* 1 97.0* 8 1 .0* 8 1 .5* 
Female (n = 2) 5 1  ± 1 61.5 ± 77.8 ± 1 00.0* 
1 2.7 3.5 32.9 
Total (n = 3) 42.0 ± 1 73.3 ± 78.8 ± 90.8 ± 
1 8.0 20.6 23.3 1 3.1 
Nate. Values are mean ± SD * one subject therefore no SD. ** excludes the male that withdrew. 
Subjects were required to attend a health screening with a General 
Practitioner in order to ensure subjects were medically fit to participate. This 
reduced the chance of participants experiencing adverse side effects due to 
the training or testing protocol. The subjects then commenced the study 
after reading and signing a consent and medical form (Appendix B & C). 
Subjects engaging in any form of RT in the past six months or who 
had previous back complaints or other musculoskeletal injuries inhibiting 
their performance in the test were asked not to participate in the study. 
Sedentary subjects were preferred because it has been proven difficult to 
isolate the improvements in performance related to the CrM 
supplementation with that from any training currently performed (Bemben 
et al., 2001). 
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3.2 Experimental Protocol 
3.2. 1 Design 
Subjects were split into two groups, a patient group (PG) and a control 
group (CG). The CG was later further split into a matched control group 
(MCG) for the comparison between disease and non-disease. All groups 
ingested CrM throughout the duration of the study in conjunction with a 
twelve-week home-based training protocol in which the groups were 
divided into subgroups of trained (PGT and CGT) and untrained limbs 
(PGU and CGU). 
The CG was included for comparison purposes between diseased and 
non-diseased individuals as well as providing a basis for eliminating 
extraneous variables. The untrained limb was also included to act as a 
within-subject control for the trained limb in both groups. For example, if an 
increase in strength and endurance parameters were seen in the CG but not 
in the PG then the lack of improvement would be due to the disease and not 
the age of the individual. 
3.2.2 Supplementation 
In healthy, active subjects, five to ten-days of 20 to 25 g·d- 1 of CrM 
has been demonstrated to increase intra-muscular Cr levels resulting in the 
ability to cope with extra training. A study by Rawson, Wehnert and 
Clarkson ( 1 999), found that studies that employed older subjects did not 
allow sufficient time for CrM loading to occur. Therefore, a loading phase 
of fourteen days was employed to enable the older subjects to effectively 
utilise the extra CrM ingested. 
All participants ingested 20 g·d- 1 of CrM during the loading phase 
(two weeks) and 5 g·d- 1 of CrM during the maintenance phase (ten weeks) 
(Appendix D). The CrM (Aussie Bodies - Victoria, Australia) was 
measured out using an electronic chemical balance scale (Mettler PM 4600 
Deltarange ). The CrM was in powder form and administered by the subject 
with the aid of a measuring scoop, one to three times a day. Subjects were 
asked to mix the supplement powder with water to make sure the subject 
stayed hydrated whilst ingesting CrM. 
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A dietary questionnaire (see Appendix F) was used, as certain foods 
are known to affect the consumption of CrM. In a diet loaded with 
carbohydrates the response to CrM intake and use is enhanced due to the 
presence of insulin (Andres et al., 1999). High caffeine consumption has 
been suggested to have an adverse effect to the ergogenic potential of CrM 
(Andres et al., 1999). Therefore the subjects were asked to restrain from 
caffeine intake for 24 hours prior to testing. 
3.2.3 Training Protocol 
Both groups participated in a twelve-week home-based light­
resistance training protocol (Appendix D). Training sessions were 
performed three times per week throughout the entire study (36 total 
exercise sessions). The training session were carried out on the knee 
extensors and knee flexors using an adjustable ankle cuff and weights 
(Australian Barbell Company - Victoria, Australia). The session consisted 
of one set of twelve repetitions of knee extension and knee flexion 
exercises, building up to two sets of twelve repetitions after the first two 
weeks. Each session lasted no more than five minutes, as only one leg was 
trained. The training limb was chosen randomly. 
The weights were set and equivalent to 30% of the subjects' maximal 
isometric force as determined from isokinetic dynamometry. The loads were 
examined regularly via the training diary with an increase every two weeks 
by an extra set or by 250 - 500 grams when they have reached the third set. 
Extra care was taken with the PG and if difficulty arose, weights/sets were 
dropped. The increases took place when subjects were able to perform the 
training sessions without any muscle soreness lasting more than one day. 
An exercise questionnaire (see Appendix E) was provided to evaluate 
the activity habits of the subjects. Activity levels were assessed to gain 
information on the fitness of the subject normal activity levels of the 
subjects. All subjects were contacted on a regular basis to ensure that they 
were continuing the program as outlined and that they had not encountered 
any problems. 
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If the subject could not cope with the discomfort they were instructed 
to take a day off training, however they were strictly informed to keep 
supplementing. Each subject was given a simple training diary (see 
Appendix F) to complete, which was used to quantify the volume of training 
as a product of repetitions and weight. 
b . )  
Figure 3. Extension and flexion training exercises . a . )  Extension exercises 
b.) Flexion exercises. 
3 .2 .4 Isokinetic Dynamometer 
Strength tests were completed on a Cybex 6000 Extremity Testing and 
Rehabil itation System (Ronkonkoma, NY), Biodex (B3) Multi Joint System 
3 Pro (Shirley, NY) or a Biodex (B2) System 2 (Shirley, NY) computer 
controlled isokinetic dynamometer. Three isokinetic dynamometers were 
operated throughout the study as the Cybex became unavailable due to over 
booking. Subjects also refused to travel to the Joondalup campus for testing 
and therefore the B2 was utilised at the University of Western Australia. As 
a result, a pilot study was performed on each dynamometer with 22 subjects 
( 1 1 = male; 1 1  = female) employing both isometric and isokinetic exercises . 
Interclass correlation coefficients (ICC) ranged from 0 .66 - 0 .92 and 0 .77  -
0 .97 for isometric and isokinetic extension exercises respectively (see 
Appendix H). 
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Each dynamometer was calibrated prior to commencing the study. The 
first session started with a verbal explanation of the aims and practical 
procedures of the study to each subject. The subject's height and weight 
measurements were recorded with a height scale and an electronic weight 
scale (Mettler IDI Multirange). With these anthropometric measurements, 
the dynamometer was adjusted to each subject individually. These 
measurements were recorded for reproduction on each testing day. 
The backrest was moved forward depending on the subject to allow 
their testing leg to push against the padding of the lever without extending 
too much. If the chair was not well equipped with back padding, foam was 
used in the lumbar region to ensure correct posture. The axis of rotation in 
the knee joint was visually aligned to the dynamometers lever arm axis. The 
correct alignment of the two is essential for the analysis of force as the 
dynamometers arm acts as the limb (Keating & Matyas, 1996). Padding on 
the dynamometer lever arm attachment was adjusted to allow for free ankle 
plantar and dorsi flexion. If the subjects complained of shin soreness an 
extra piece of foam was used to cover the foreleg. 
A diagonal shoulder and a lap seat belt secured the subject's trunk 
against the chair. A velcro strap positioned firmly at the distal thigh secured 
the test leg to the chair. These straps help stabilise the upper body and upper 
limb preventing unwanted movements (Evetovich et al., 2001). The non-test 
leg was left to hang free at about 90°- knee flexion. The operator moved the 
subject 's leg through the entire range of movement (ROM), limits of motion 
of a limb, to ensure that the lever arm and the subject's leg follow the same 
rotation and gravitational corrections was then calculated at 45°- knee 
flexion on both the Cybex and B2, whereas the leg was placed in full knee 
extension for B3. An extendable goniometer (Lafayette Instrument 
Company) was needed to acquire this angle on the B2. 
A practice test was employed to familiarise each subject to the testing 
velocities used. Two repetitions were performed at submaximal effort, the 
last repetition was performed at full maximal effort to familiarise the 
subject. After the subject felt comfortable with the different tasks, the actual 
exercise was started. 
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The test session lasted no more than one hour and included three 
isometric contractions of the knee extensors and knee flexors at two 
different angles ( 45° and 60°) with a 30-second rest period between each 
angle. An Ambassador stopwatch (Accusplit, USA) was used to measure the 
rest period. The short rest was chosen as it is known to show increased 
torque production by an average of 5% when compared with a protocol with 
no rests which is shown to portray more of a declining trend (Keating & 
Matyas, 1996). 
The subjects were then instructed to exert four extension and flexion 
MVC's as rapidly and as hard as possible over four constant angular 
velocities 60°, 120°, 180° and 240° s- 1 (slow to fast) with a 30-second rest 
between each velocity. Two minutes after the exercise test was performed 
and recorded the endurance test begun. This consisted of five sets of fifteen 
repetitions at a velocity of 180° s- 1 with a 30-second rest between sets. The 
subject was instructed to concentrate on extension repetitions, as flexion 
was not measured in this test. For this reason the flexion velocity was set at 
450° s- 1 on the B2 to prevent any torque production. The subject then rested 
for five minutes and the protocol was repeated with the non-trained leg for 
comparison. The procedure was repeated at the end of weeks two, seven and 
twelve (Appendix C). All sessions were performed under the supervision of 
the same investigator. All testing was performed while receiving strong and 
frequent encouragement both verbally and visually on screen. 
Measurements of torque, work and power were assessed in each exercise. 
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a.) 
Figure 4 .  Isokinetic dynamometers . a . )  Cybex 6000 Extremity Testing and 
Rehabilitation System (Ronkonkoma, NY). b . )  Biodex System 2 (Shirley, 
NY) . c . )  Biodex Multi Joint System 3 Pro (Shirley, NY) . 
3 .3 . 5  Body Composition (DEXA) 
Body composition measurements were assessed using a Norland XR -
46 Dual Energy X-ray Absorptiometer (DEXA) via pencil beam technology . 
The DEXA scans are used to measure bone and soft tissue composition in 
vivo, also permitting the assessment of whole-body and regional body 
composition (Lukaski, 1 997) . Dual energy x-ray absorptiometer scanning is 
a very reliable (r = 0 .99) and accurate means (Coefficient of Variation = 0 .5  
- 1 %)  of quantifying body composition for regional as  well as  whole body 
parameters (Maud & Foster, 1 995 ;  Kreider et al . ,  1 996) . 
The DEXA scans separate the body tissue into three chemical 
components, lean soft tissue, fat soft tissue, and bone (Kreider et al . ,  1 998) .  
Scans were taken of the whole body with the left and right upper legs 
singled out after to quantify the mass of the limb segment (see Appendix G) . 
The upper leg data was achieved by repositioning the cursor from individual 
DEXA scans to the most superior point of the greater trochanter to the 
lateral epicondyle of the femur. 
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The tests were performed prior to the commencement of the exercise 
program and supplementation and repeated at the end of week twelve 
(Appendix D). Before scanning all participants were required to take off all 
removable objects containing metal (i.e. jewellery, glasses, and clothing 
with buttons or zippers). Scans were performed with the subject lying in a 
supine position along the scanning table's centre line of the longitudinal 
axis. The scan took approximately five minutes to complete. 
The scanned bone mass for each region, was totalled to determine 
whole body values. Lean body mass, FM, and FFM were also recorded from 
the computer software for whole body, and trained and untrained lower 
limbs. 
3.3.6 Blood 
The serum Cm level was measured in the first week before 
supplementation and at the end of week twelve using a portable Reflotron 
Spectrophotometer (Boehringer-Mannheim - Pode, Czech Republic) 
(Appendix D). A site on the fingertip was cleaned using an alcohol swab 
where the lancet (Boehringer-Mannheim - Pode, Czech Republic) was to 
puncture the skin and draw blood into a heparinized capillary tube. The 
blood was then placed on a Cm assay strip (Roche Diagnostics -
Mannheim, Germany) in which the Reflotron Spectrophotometer analysed 
the circulating Cm levels. 
3.3 Data Analysis 
Torque (peak and low values), work and power were recorded for 
each isometric, isokinetic and endurance test. However not all tables were 
displayed in the results section due to the large amount of data recorded. 
Isometric data for the first angle, 45°, and isokinetic data at predetermined 
speeds of 120° s- 1 and 240° s- 1 were not included as they showed little or no 
variation in comparison to data obtained from the second isometric angle, 
60°, and velocities of60° s- 1 and 180° f 1 . 
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The fatigue index was determined as the measurement of PT for the 
last five repetitions (last third) divided by the first five PT values (first third) 
and expressed as a percentage decline in work performance (W estblad, 
Svedenhag & Rolf, 1996). Total training volume was measured by firstly 
multiplying the amount of weight lifted by the numbers of repetitions 
performed, then by the number of sets performed in one session. The 
training volume for each session was added together to obtain the total 
training volume. 
These variables were compared in the patient population group prior 
to the training program and at the end of week twelve. In addition, the 
results obtained from the trained leg were compared with the non-trained 
leg. The patient data were then compared with the healthy subject's data, 
which was analysed the same way. In line with similar research in this area 
values in the results section are expressed as mean ± standard error of mean 
(SEM) unless otherwise stated. 
3.4 Statistics 
Differences between exercise parameters obtained at given velocities 
and angles were tested for significance using a one-way analysis of variance 
(ANOV A) with repeated measure design. Standard statistical methods were 
used to calculate the mean, standard deviations (SD) or SEM. Serum Cm 
levels and DEXA scans were analysed using a t-test with repeated measures. 
Differences were considered significant if the p value was < 0.05 (Fenter, 
Bellew, Pitts & Kay, 2003). 
3.5 Limitations 
The major limitation of the study was the variability between patients 
and the lack of numbers. An individuals' response differed as well as their 
physical abilities due to the progression of their disease. Another limitation 
was that the control subjects were sought out through advertisements in the 
local community therefore it is difficult to say whether the participants were 
a true representation of the general population. 
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Further limitations with the study were that supplementation and the 
training exercises were performed in the subject' s  home not directly 
supervised by the investigator. A considerable amount of trust was placed 
on the subject to ensure both the supplementation and the training was being 
followed as instructed. An additional limitation to training was that no 
between-group comparisons of the contralateral limb were tested. Due to the 
low subject numbers only within-group comparisons were conducted and it 
has been known with this design that contralateral strength increases may be 
due to familiarisation with the test exercise and procedures (Munn et al. ,  
2004). Another major limitation was that three dynamometers were used to 
test the subjects due to transport and other unforeseen problems, which may 
also account for the variability between results. Lastly, in regards to the 
training volume, a low training intensity was implemented based on 
previous work with CrM supplementation and training in elderly males. The 
muscular weakness of the patient population was also kept in mind when the 
training intensity was employed. Due to the lack of studies in this area and 
the unknown responses to heavy RT, a lowered intensity was instigated. 
To control most of the above limitations the training was monitored 
through the completion of a training diary and supplementation was pre­
packed and a reliable measuring tool was implemented for the subject to 
calculate the proper dosage needed. A pilot study was also conducted (n = 
22) to compare the data output of PT and TW between all three isokinetic 
dynamometers (see Appendix H) however, this showed that for the three 
isokinetic dynamometers, reliability was low for some measures, accounting 
for the majority of variability seen between results. 
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CHAPTER FOUR 
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4. 1 Exercise Training 
4. RESULTS 
Figure 5 below shows the average training volumes for the CG and 
PG calculated from their training diaries. The CG (n = 6) performed an 
estimated mean total volume of 3070 ± 280 J (± SEM) compared with the 
PG [n = 2 (one female, one male)] who averaged 424 1 ± 2234 J over the 
twelve-weeks . The MCG [n = 2 (one female, one male)] measured a mean 
total volume of 3047 ± 374 J, a 39% difference from the PG pairs . 
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Figure 5. Total training volumes for control group (n = 6) and patient group 
(n = 2) for twelve-weeks (Mean ± SEM). 
The total volume of training for the two pairs can be seen in Figure 6. 
The total training for the female pair was 2673 J and 2007 J for the control 
and patient respectively. As for the male pair the control ' s  total training was 
3420 J compared with 6476 J of the patient .  
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Figure 6. Total training volumes for the matched control (n = 2) and patient 
(n = 2) pairs over twelve-weeks. 
Subjects started with one set of twelve repetitions on different weights 
[CG = 2 .7  ± 0 .3  kg; PG = 2 . 5  ± 0 .7 kg (± SD)] obtained from 30% of their 
initial MVC values recorded in the pre BL week. Subjects were instructed to 
increase their training volume via increased sets and/or weights on a regular 
basis as seen in Figure 7 .  
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Figure 7. Weekly training volumes for control (n = 6) and patient (n = 2) 
groups over twelve-weeks (Mean ± SEM) . 
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On average the PG performed slightly higher weekly training loads 
than the CG over the twelve-weeks. Average training volumes for the week 
ranged from 118 - 362 J and 261.8 - 513 J for the CG and PG respectively. 
The MCG performed total training volumes of 99 - 379.5 J weekly. 
Training diaries were also analysed for subject adherence. The CG 
missed a total of seven sessions compared with the PG missing three 
sessions (out of 36). The compliance was 98.6% and 95.8% respectively. 
There was 100% compliance with the MCG pairs. Overall a significant 
difference was not seen (p>0.05) over the twelve-week training programme 
for total volume. 
4.2 Strength Testing 
The isometric PT responses of the CG and PG at 60° for knee flexion 
can be seen in Figure 8. Baseline strength started at 49 ± 27 Nm and 63 ± 36 
Nm for the trained and untrained leg of the PG. The CG averaged a BL 
strength of 57.8 ± 8 Nm and 53.1 ± 9.4 Nm for the trained and untrained 
limb respectively. The trained limb of the patients decreased in Week 2 
(-18.4%) then increased by 16.3% and 12.2% in Week 7 and Week 12 
compared with BL values. The untrained limb decreased (-9.5% and -
17.5%) in Week 2 and Week 7 respectively, finally increasing in Week 12 
(5.6%). On the other hand the CG both trained (7.6%, 16.2% and 20.8%) 
and untrained (5.9%, 15.7% and 16.7%) increased steadily over the twelve­
weeks. However a significant difference was not seen (p>0.05) over the 
twelve-week training programme. 
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Figure 8. Isometric strength changes at 60° of the flexors for trained and 
untrained limbs in the control (n = 6) and patient (n = 2) groups (Mean ± 
SEM). 
Figure 9 shows the responses of the CG and PG over time for 
isometric PT values at 60° for the knee extension. Basel ine strength for the 
trained and untrained limbs of the PG were 1 33 . 5  ± 52 .5  Nm and 1 48 . 5  ± 
65 . 5  Nm. The CG averaged an initial strength of 1 5 5 . 8  ± 25 Nm and 1 5 1 . 1  ± 
1 8 . 8  Nm for the trained and untrained limb respectively .  The PGT limb 
increased strength by 2 1 . 8% in the second week, slightly decreased in the 
seventh ( 1 4 .2%) and increased to 24 .3% by the final week compared to BL 
figures .  Both the untrained limb of the PG and the trained limb of the CG 
increased in Week 2 (6. 1 % and 1 1 . 8%) and slowly declined over Week 7 
(5 . 1 %  and 6.6%) and Week 1 2  (-6.4% and 6 . 1 %) .  The untrained limb for the 
CG decreased in Week 2 (-4 .2%) until increasing in Week 7 (2%) and again 
in Week 1 2  (3 .2%) . A significant difference was not seen (p>0.05) over the 
twelve-week training programme . 
57 
240 
200 • PGT 
Peak D PGU 
torque 1 60 • cGT 
(Nm) CGU 
1 20 
80 
BL 2 7 1 2  
Week 
Figure 9. Isometric strength changes at 60° of the extensors for trained and 
untrained limbs in the control (n = 6) and patient (n = 2) groups (Mean ± 
SEM) . 
Figure 1 0  shows the responses of the CG and PG over time for 
isokinetic PT values at 60° s- 1 for the knee flexors . By Week 2 PGT had 
decreased by 1 0 .4% whilst PGU (6 .4%), CGT (4%) and CGU (4.4%) 
increased . The PGT, PGU, CGT and CGU limbs all increased by the 
seventh week ( 1 1 . 8%, 8 . 6%, 9.2% and 1 3 . 1  % respectively). Both PGU and 
CGT again by Week 1 2  ( 1 2 .3% and 1 0 .9%), PGT and CGU on the other 
hand tended to decrease (0. 1 %  and 5%) in Week 1 2  compared with BL 
values .  A significant difference was not seen (p>0 .05)  over the twelve-week 
training programme . 
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Figure J O. Isokinetic strength changes at 60° s- 1 of the flexors expressed as 
a mean percentage from BL values for trained and untrained limbs in the 
control (n = 6) and patient (n = 2) groups (Mean ± SEM) . 
Figure 1 1  shows the responses of the CG and PG over time for 
isokinetic PT values at 1 80° s- 1 for the knee flexors . Over the twelve-weeks 
CGU slowly declined below BL values (Week 2 = -3 .7%; Week 7 = -5 . 3%;  
Week 1 2  -5 . 8%) . The PGU limb started below BL levels (- 1 2 .6%) in Week 
2. By Week 7 and 1 2  the limb had improved (48 . 8% and 24 .9%) from BL. 
As for PGT the limb increased over the twelve-weeks (4 . 5%, 1 1 .6% and 
7 . 8%) just like CGT ( 1 7 .2%, 3 1 . 1 %  and 24 . 8%). A significant difference 
was not seen (p>0 .05) over the twelve-week training programme. 
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Figure 1 1 . Isokinetic strength changes at 1 80° s- 1 of the flexors expressed as 
a mean percentage from BL values for trained and untrained limbs in the 
control (n = 6) and patient (n = 2) groups (Mean ± SEM). 
Figure 1 2  shows the responses of the CG and PG over time for 
isokinetic PT values at 60° s- 1 for the knee extension. In Week 2 both PG 
and CG trained limb and the CG untrained limb increased ( 1 3  . 1  %, 2 .2% and 
2 .2% respectively). The PGU limb decreased (- 1 2 . 3%) from BL values .  By 
Week 7 PGT, PGU and CGU increased again ( 1 8 .5%, 1 . 5% and 1 0 . 1  %) 
whilst CGT decreased slightly ( 1 .4%) . Towards the end PGT, CGT and 
CGU also started to decline (7 .3%, 0 .6% and -0. 8%) where as the untrained 
limb of the PG increased to 2 .5%.  A significant difference was not seen 
(p>0 .05) over the twelve-week training programme . 
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Figure 12. Isokinetic strength changes at 60° s- 1 of the extensors expressed 
as a mean percentage from BL values for trained and untrained limbs in the 
control (n = 6) and patient (n = 2) groups (Mean ± SEM) . 
Figure 1 3  shows the responses of the CG and PG over time for 
isokinetic PT values at 1 80° s- 1 for the knee extension. PGU started below 
BL figures in Week 2 (- 1 1 . 5%) and slowly started to increase (Week 7 = 
-4. 1 %  and Week 1 2  = -0 . 8%). The CGT limb kept increasing above BL 
values (Week 2 = 4 .6%; Week 7 = 6 .4%; Week 12  = 8 .3%).  Both PGT and 
CGU started off increasing in Week 2 (6 . 8% and 6 .9%) and Week 7 ( 1 2 . 7% 
and 8 .7%) dropping off in Week 1 2  ( 1 2 . 3% and 3 .9% respectively) . A 
significant difference was not seen (p>0.05) over the twelve-week training 
programme. 
61  
1 60 
1 40 
Peak 1 20 
torque 
(Nm) 1 00 
80 
60 
2 7 
Week 
1 2  
• PGT 
D PGU 
• cGT 
CGU 
Figure 13 .  Isokinetic strength changes at 1 80° s- 1 of the extensors expressed 
as a mean percentage from BL values for trained and untrained limbs in the 
control (n = 6) and patient (n = 2) groups (Mean ± SEM) . 
Figure 1 4  shows the responses of the CG and PG over time for the 
endurance protocol performed at 1 80° s- 1 • It represents the PT changes for 
the untrained and trained knee extensors . At BL both PGT and PGU were 
higher ( 1 1 2 .4 ± 5 . 8  Nm; 1 1 5 . 1  ± 4 .8  Nm) than the CG (Trained = 92.2 ± 
1 .6 Nm; Untrained = 94 ± 1 . 8 Nm).  By Week 2 the CG (Trained = 98.3 ± 
2 .3  Nm; Untrained = 1 0 1 . 5 ± 2 .5  Nm) had increased whereas the PG both 
trained and untrained declined ( 1 05 .9  ± 5 .6  Nm; 1 09 .6  ± 2 . 5  Nm) .  By Week 
7 PGT, CGT and CGU increased their PT values above BL levels ( 1 1 4 .2 ± 
5 Nm; 1 0 1 . 8 ± 1 . 7 Nm ; 1 03 .2  ± 1 . 8 Nm), the PGU limb fell slightly short 
( 1 1 5  ± 4 .8  Nm) .  Over the twelve-weeks the CG had increased its strength 
from BL levels  (Trained = 1 0 1 .9 ± 1 .9 Nm; Untrained = 96 .7 ± 1 . 7 Nm) 
compared with the PG (Trained = 1 05 ± 4 . 7  Nm; Untrained = 1 1 3 .2 ± 
4 .9  Nm) .  A significant difference was not seen (p>0 .05) over the twelve­
week training programme. 
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Figure I 4. Strength changes of the extensors in the endurance protocol at 
1 80° s- 1 for trained and untrained limbs in the control (n = 6) and patient 
(n°= 2) groups (Mean ± SEM) . 
Figure 1 5  shows the responses of the CG and PG over time for the 
endurance protocol performed at 1 80° s- 1 • Representing the STW generated 
for the untrained and trained knee extensors . The CGT limb increased 
throughout the twelve-weeks (BL = 1 030 .6  ± 25 .6  J; Week 2 = 1 1 26 ± 
4 1 .3 J ;  Week 7 = 1 1 56 ± 3 5 . 8  J ;  Week 1 2  = 1 1 89 .8  ± 44 .3  J) where as the 
untrained limb started to drop off at Week 7 only to improve by Week 1 2  
(BL = 1 0 1 7  ± 40.2 J ;  Week 2 = 1 079 ± 42.9 J ;  Week 7 = 1 066 ± 39 .2 J ;  
Week 12  = 1 082 .9 ± 27 .2  J) . The PGU limb decreased overall (BL = 1 206 .7  
± 66 .5  J ;  Week 2 = 1 1 78 .6  ± 40.9 J ;  Week 7 = 1 275 .9  ± 52 .6  J ;  Week 12 = 
1 1 06.9 ± 1 0 1 . 7 J) where as PGT increased up until Week 7 dropping in 
Week 1 2, staying above BL figures (BL = 1 1 1 2 .6  ± 65 . 8  J; Week 2 = 1 340 . 5  
± 74.9 J ;  Week 7 = 1 370.3 ± 69 .6 J ;  Week 1 2  = 1 1 8 1 .4 ± 73 .9  J). A 
significant difference was not seen (p>0 .05)  over the twelve-week training 
programme. 
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Figure 15. Set total work changes of the extensors in the endurance protocol 
at 1 80° s- 1 for trained and untrained limbs in the control (n = 6) and patient 
(n = 2) groups (Mean ± SEM) . 
Figure 1 6  represents the fatigue index of the CG and PG over time for 
the untrained and trained knee extensors . Fatigue index for the PG declined 
from BL to Week 2 for trained (88 .4  ± 5 .9 %; 78 . 3  ± 2 . 3  %) and untrained 
(84 . 5  ± 4.2 %; 84 ± 2 .9  %) . From BL the fatigue index increased in Week 2 
for the CGT (87 .9 ± 2 .6  %; 88  ± 3 .4 %) and CGU (83 . 3  ± 3 .4 %;  86 .6 ± 3 . 3  
% respectively) . By  Week 7 all groups continued increasing (PGT = 80 .8  ± 
3 .4 %;  PGU = 87 .2 ± 1 .2 %;  CGT = 89 . 1 ± 3 %;  CGU = 88 . 3  ± 3 .2 %), 
although PGT was sti ll below BL values .  This trend continues into Week 1 2  
where PGT was still below B L  (8 1 . 5 ± 3 . 9  %). Although PGU, CGT and 
CGU stayed above BL values they had decreased slightly from Week 7 
(PGU = 85 . 3  ± 2 . 8  %; CGT = 88 .2 ± 3 .2 %;  CGU = 87 .5  ± 3 %). A 
significant difference was not seen (p>0 .05)  over the twelve-week training 
programme . 
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Figure 1 6. Changes in the fatigue index of the extensors at 1 80° s- 1 for 
trained and untrained limbs in the control (n = 6) and patient (n = 2) groups 
(Mean ± SEM) . 
Figure 1 7  represents the lowest torque generated by the trained and 
untrained extensors during the endurance protocol for the CG and PG over 
time . The COT and the CGU limbs improved values of lowest torque 
throughout the twelve-weeks (BL = 58 . 9  ± 2 .6  Nm, 60 ± 3 Nm; Week 2 = 
67 . 1 ± 3 . 8  Nm, 63 . 5  ± 3 .2  Nm; Week 7 = 70. 1 ± 2 . 5  Nm, 66 ± 3 . 9  Nm; 
Week 12 = 70 . 5  ± 3 . 5  Nm, 67 .2 ± 3 .9 Nm respectively) . The POT limb 
decreased below BL levels by Week 1 2  (BL = 59.6 ± 6 . 1 Nm; Week 2 = 
52 .3  ± 4 . 5  Nm; Week 7 = 58 . 8  ± 4.4 Nm; Week 1 2  = 52 .4 ± 4.6 Nm) where 
as POU improved (BL = 54.2 ± 6.2 Nm; Week 2 = 52 . 5  ± 6 .6  Nm ; Week 7 = 
62. 1 ± 3 . 9  Nm; Week 1 2  = 57.4 ± 3 . 5  Nm). A significant difference was not 
seen (p>0.05)  over the twelve-week training and CrM supplementation 
period. 
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Figure 1 7. Changes in the lowest torque generated by the extensors at 
1 80° s- 1 for trained and untrained limbs in the control (n = 6) and patient (n = 
2) groups (Mean ± SEM) . 
4.3 Body Composition (DEXA) 
Table 2 represents the total amount of body mass, LBM and FM of the 
whole body for all groups .  Body mass increased for the CG and MCG (2 .3% 
and 5% respectively) and decreased for the PG (-0 .3%) .  The LBM increased 
for all groups (CG = 4.4%; MCG = 4 . 7%; PG = 2 .2%) and FM decreased for 
both CG and PG (- 1 . 8% and -3% respectively) but increased for the MCG 
(4.2%). No significant difference was seen (p>0 .05)  in any group over the 
twelve-week training programme for body mass, LBM or FM. 
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Table 2. 
Whole body Dual Energy X-ray Absorptiometer values pre- and 
post-supplementation and training for control group (n = 6), matched 
control group (n = 2) and patient group (n = 2). (Mean ± SEM). 
Body mass LBM Fat 
(kg) (kg) (kg) 
n Pre Post Pre Post Pre Post 
Control 6 (CG) 
70.4 ± 72 ± 45.2 ± 47.2 ± 22.1 ± 21.7 ± 
8 9.1 3.8 4.6 4.2 3.9 
2 (MCG) 
78.5 ± 82.4 ± 50.9 ± 53.3 ± 24 ± 25 ± 
0.7 4.2 6 8 8.8 7.9 
Patient 2 
91 ± 90.8 ± 49.8 ± 50.9 ± 37.2 ± 36.1 ± 
14.1 13.1 7.8 8.5 21.8 21.4 
Table 3 represents the total amount of LBM and FM of the trained and 
untrained limbs for the PG, CG and MCG. The LBM increased by a small 
amount for both trained (CG = 5.4%; MCG = 9.3%; PG = 6.3%) and 
untrained (CG = 3.1%; MCG = 9.5%; PG = 6.2%) limbs across all groups. 
Fat mass decreased in the trained (CG = -2.4%; MCG = -5.9%) and 
untrained (CG = -5.9%; MCG = -6%) limbs of the CG and MCG and the 
untrained limb of the PG ( -3 .2 % ) while increasing for the trained limb 
(1.9%). No significant difference was seen (p>0.05) over the twelve-week 
training programme for LBM or FM. 
Table 3. 
Limb segment DEXA values pre and post supplementation and training for 
control group (n = 6), matched control group (n = 2) and patient group (n = 
2). (Mean ± SEM). 
LBM Fat 
(kg) (kg) 
n Pre Post Pre Post 
Control 
CGT 6 (CG) 5.6± 0.6 5.9 ± 0.7 4.2 ± 0.8 4.1 ± 0.7 
2 (MCG) 6.4 ± 1 6.6 ± 1.3 5.1± 1.5 4.8 ± 1.1 
CGU 6 (CG) 5.4 ± 0.6 5.9± 0.8 4.2 ± 0.8 4.1 ± 0.7 
2 (MCG) 6.3 ± 0.9 6.9 ± 1.4 5 ± 1.5 4.7 ± 1 
Patient 
PGT 2 6.3 ± 2 6.7± 2 5.2± 2 5.3 ± 2.4 
PGU 2 6.5 ± 1 .2 6.9 ± 1 .6 6. 1 ± 3 6 ± 3 . 1  
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4.4 Creatinine 
Figure 1 8  below shows the Cm values of CG, MCG and PG, pre and 
post the training and supplementation programme. Creatinine levels at BL 
were 55 . 8  ± 1 1 .6 µmol/1 for the PG and 62 .2 ± 5 . 3 µmol/1 for the CG.  A 
slight increase was seen in the both CG (7 1 . 5 ± 6 .4 µmol/1) and PG (64 . 1 ± 
1 9 .9 µmol/1) by the final week. The MCG also increased (65 . 7  ± 1 6 .2 µmol/1 
to 72.2 ± 2 1 . 7 µmol/1) . No significant difference was seen (p>0 .05) over the 
twelve-week programme, for neither time nor group in serum Cm values .  
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Figure 1 8 . Serum creatinine values pre and post supplementation and 
training for control (n = 6), matched control (n = 2) and patient (n = 2) 
groups. (Mean ± SEM). 
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5. 1 Exercise Training 
5. DISCUSSION 
In the present study both the CG and MCG trained at a volume 28% 
lower than that of the PG due to the patients being 14.3% and 1.74% weaker 
than the CG for trained and untrained limbs in isometric exercises. As all 
subjects ingested CrM throughout the twelve-weeks no data can be described 
for improvements of exercise training alone. However, studies involving 
neuromuscular disorders support the role of RT, providing that the training is 
progressive and supervised (Spector et al., 1997). 
A study by Alexanderson et al. (1999) demonstrated significant 
improvements in six out of ten patients for the upper and lower limbs 
compared with BL values. Spector et al. (1997) found that almost all patients 
encountered some degree of improvement in PT production for each muscle 
group tested, although increases seen as a result of the training implemented 
showed no statistical significance (Spector et al., 1997). A study by 
Wiesinger et al. (2000) also showed significant progress in muscular 
strength, oxygen uptake and the overall health of the patients with no rise in 
disease activity due to the RT programme performed. 
There are many possible reasons as to why the strength increases may 
not be statistically significant. The first could be due to the low numbers 
involved in both the CG (n = 6) and PG (n = 2) group and the insufficient 
training volume and intensity applied in the home-based RT programme 
(Ahtiainen, Pakarinen, Alen, Kraemer & Hakkinen, 2003; Arnardottir et al., 
2003). The training volume was chosen based on the work of a previous 
researcher and with the muscular weakness of the patient population in mind. 
Low participation numbers were unavoidable in this study due to the 
extended waiting period prior to recruitment and testing. This was further 
delayed as a result of equipment failure, taking one year for experts to realise 
that the isokinetic dynamometer was not repairable. Also testing location and 
the duration of testing played a big role as many of the patients lived an hour 
away, planing holidays and/or starting full time work, which would have 
interrupted testing. Initial numbers for participation were 18 controls and 16 
patients. 
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Another reason could be that certain muscles may be affected 
differently due to muscle degeneration as the disease progresses. These 
affected muscles are less likely to respond to the RT as well as nonaffected 
muscles or muscles with a smaller amount of affected fibres (Spector et al., 
1997). An additional reason could be due to the prescribed drugs effect on 
capillary numbers and myofibril mass (Cherin et al., 2002). Prednisone and 
Prednisolone have been known to decrease the amount of capillaries and 
reduce the size of myofibrils (Wiesinger et al., 2000). Steroid therapy can 
also cause atrophy in selected muscles ( especially in muscles with 
prevalence for type II muscle fibres) (Bromberg & Carter, 2004). It has been 
suggested that this reduction could be due to the inhibition of protein 
synthesis and/or as a result of reduced myofibril mass (Wiesinger et al., 
2000). It is also likely that a more sedentary lifestyle may result in some 
degree of disuse (Spector et al., 1997). 
The subjects were informed during the first few weeks of training that 
they might encounter slight muscle soreness. This was not seen in the CG 
and the PG reported only slight fatigue and mild soreness post exercise 
which disappeared after a few hours or at the latest the following day. 
Overall, previous studies involving strength training emphasise the 
importance of physical exercise and the possible improvements that could be 
achieved with patients suffering from different myopathies (Spector et al., 
1997; Wiesinger et al., 2000). 
5.2 Creatine Supplementation 
In the present study all subjects were required to ingest CrM over the 
twelve-weeks, whilst training one leg and resting the other. The effects of 
CrM supplementation alone can be seen in the strength changes of the 
untrained limb for PGU (2.5%) and for CGU (9.3%) in isokinetic extension 
exercises. No significant increases were reported and it was not known 
whether the 20 g.d- 1 of CrM ingested in the initial loading phase increased 
the intramuscular stores of Cr, as these measurements were not assessed. 
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As previously stated ingestion of CrM has found to be advantageous in 
numerous studies conducted with young and elderly individuals. It can 
increase intramuscular stores of TCr and PCr, increasing muscular strength 
and muscular functional capacity (Casey et al., 1996; Smith et al., 1998; 
Eijnde et al., 2003; Louis et al., 2003). 
Several studies by Tarnopolsky et al. (1997), Tarnopolsky and Martin 
(1999), Tarnopolsky and Parise (1999), Tarnopolsky and Beal (2001) and 
Tarnopolsky, Parshad, Walzel, Schlattner and Wallimann (2001) have 
studied the effects of CrM supplementation with individuals diagnosed with 
various muscle diseases including IM. It is believed that these patient 
populations would benefit from CrM supplementation due to their low 
intramuscular Cr concentrations, similar to that found in elderly individuals 
(Rawson et al., 1999; Tarnopolsky & Parise, 1999). 
Louis et al. (2003) showed increases in muscle mass and muscle 
endurance with PT strength for knee extension increasing by 37% and knee 
flexion by 12.4%. After three months of CrM ingestion, the patients were 
able to maintain 75% of their MVC for twice the time. These improvements 
were maintained after the two month wash out period, even when the 
intramuscular Cr levels were restored to BL values (Louis et al., 2003). 
However, Lambert et al. (2003) found that CrM ingestion did not 
significantly increase intramuscular stores of TCr or PCr nor did it improve 
TW during the exercises. A slight increase was seen in the knee extension 
exercises however a decline was present for knee flexion (Lambert et al., 
2003). 
In the present study isometric strength in the untrained leg increased 
over the twelve-weeks of supplementation at 60° by 13% and 16.1 % for 
flexion of the PGU and CGU limbs respectively and 2.2% and 0.5% for the 
extension exercises. No significant differences were found. Flexor muscles 
seemed to benefit more from CrM than extensor muscles and the PG 
improved more than the CG. 
Isokinetic flexion strength also increased over time except for the 
CGU limb at 180° s- 1 • Flexion strength changes ranged from 12.3 - 24.9% 
and -5.8 - 5.3% for the PGU and CGU limbs over 60° s- 1 and 180° s- 1 . 
Extension strength decreased for the PGU limb at the faster velocities and 
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the CGU limb decreased at the slower velocities. Extension strength varied 
from -0.8 - 2.5% (PGU) and -0.8 - 3.9% (CGU). The lack of significant 
strength increases could be due to the light intensity of the training 
employed and possibly insufficient loading of CrM to influence changes in 
muscle mass and strength. 
No significant changes were seen in the endurance protocol. Strength 
values for the untrained limb varied from -3.5 - 2.7% (PGU) and -3.2 -
0.9% (CGU). The STW changed between -23.3 - 15.3% and -2.2 - 8.7% 
for the PGU and CGU limbs overtime. Differences in the fatigue index 
ranged from -6.3 - 8.5% and -0.8 - 7.2% for the PGU and CGU limbs. A 
greater difference was seen in the lowest torques generated in each set for 
the PGU (-5.9 - 38.1 %) compared with the CGU limb (1.7 - 12.6%). 
Another encouraging characteristic of the CrM ingested was that no 
major health problems were reported as a result of CrM ingestion in this 
study. Only four of the ten subjects complained of minor discomforts such 
as bloating with one complaint of an irritable stomach. 
Improvements in the untrained limb, despite no significance, could be 
due to the improved endurance capability of the muscles and its ability to 
recover more readily between bouts. There are a number of potential 
reasons why CrM ingestion did not significantly affect muscular strength. 
Firstly the loading period may not have been long enough. Secondly the 
amount of CrM ingested may have been insufficient to elicit an increase in 
intramuscular Cr stores that would normally be effective in healthy 
individuals (Chetlin, Gutmann, Tarnopolsky, Ullrich & Yeater, 2004). This 
would have required the use of muscle biopsies to determine the amount of 
Cr uptake into the muscles. Thirdly it is not known whether the functioning 
of the Cr transporter within the cells of patients functions normally or that it 
can synthesis large amounts of oral CrM. Lastly the subjects may not have 
complied with the instructions given by the investigator in regards to the 
daily dose of CrM (Chetlin et al., 2004), however this was not reported 
during the study as the containers used to store the CrM were reviewed by 
the investigator. 
No study to the writers knowledge has demonstrated the effects of RT 
on strength in the trained and untrained limbs of patients with PM and DM. 
It has been suggested that neural adaptation due to exercise can cross over 
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from the limb being trained to the untrained limb, which may result in 
increases in PT values (Housh et al., 1992; Evetovich et al., 2001; Munn et 
al., 2005). 
A study by Evetovich et al. (2001) found significant increases over 
time in both the trained (15.5%) and untrained (5.5%) limbs of the trained 
group however no significant difference were seen in the controls, or in the 
electromyography amplitude of either group. They concluded that in the 
absence of electromyography changes, increases in PT were due to 
hypertrophic factors and/or changes with the muscle or surrounding 
muscles involved in knee extension training (Evetovich et al., 2001). 
However, neural adaptations are considered more likely for any 
changes in the untrained limb and are possibly related to increases in the 
stimulation of motor units, increasing the flow of impulses to the untrained 
muscle and/or the ability of the untrained muscles to adopt a structural 
support or balance to cope with the trained limb producing maximal 
strength measures (Housh et al., 1992; Evetovich et al., 2001; Munn et al., 
2005). 
5.3 Strength Training 
The present study found no significant changes in any of the exercises 
performed, however, both flexion and extension strength increased over the 
twelve-week supplementation and training period. Isometric strength in the 
trained limb increased at an angle of 60° by 30.7% and 6.7% for extension 
of the PGT and CGT limbs respectively and 16% and 21.1 % for flexion. 
Isokinetic flexion strength increased with time for both trained limbs over 
velocities of 60° s-1 and 180° s-1 . Flexion strength ranged from 0.1 - 7.8% 
and 10.9 - 24.8% for the PGT and CGT limbs respectively. Extension 
strength also increased by 7.3 - 12.3% and 0.6 - 8.3% for the PGT and 
CGT limbs. Again no statistically significant differences were found. 
It is possible that there was sufficient uptake of Cr into the muscles to 
show slight improvements in strength without observing any increases in 
lower limb muscle mass. A placebo group would have been needed to 
prove this, however the overall strength increases and recovery at the end 
of each set in the endurance protocol could possibly relate the 
improvements to CrM supplementation and its ability to prolong fatigue. 
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The increases could also be due to neural adaptations in the muscles, 
however, this was not measured. 
In the endurance protocol, strength values decreased with every set as 
expected due to fatigue. However, over time strength improved for all 
groups slowing slightly by the final week for both trained and untrained 
limbs. Changes in strength ranged from -6.9 - 5.5% and 5.5 - 11.8% for the 
trained limbs of the PG and CG. The STW varied from 11.2 - 18.2% and 
10.2 - 18.6% for PGT and CGT limbs. Differences in the fatigue index 
ranged from -15.1 - 5.5% and from no change to 8.9% in the PGT and 
CGT limbs respectively. Lowest torques varied from -19.8 - -1.8% (PGT) 
and 9.7 - 26.8% (CGT) over twelve-weeks of supplementation and 
training. 
The slight decreases seen in most exercises between Week 7 and 
Week 12 in the present study could be due to reasons other than the absence 
of an ergogenic effect. The patients may have lost motivation due to the 
insufficient intensity and volume of the RT program and that it was home­
based therefore being rarely supervised, this was not indicated in the 
training diaries. However, lower intensities and volumes were used in the 
RT because it was not known what weights would have been suitable for 
the diseased population. There is a possibility that the maintenance doses of 
CrM became ineffective over time. If there were insufficient uptake of Cr 
into the muscles any improvements would not have been sustained by the 
maintenance phase. Also the recovery time between protocols and 
endurance sets may not have been long enough for the groups to recover, 
possibly suggesting that the individuals were partially fatigued before even 
commencing the endurance protocol. 
Chetlin, Gutmann, Tarnopolsky, Ullrich and Yeater (2004) 
performed a twelve-week RT program combined with CrM 
supplementation with 20 patients diagnosed with Charcot Marie Tooth 
disease. No benefits were found for adding CrM to RT however increases 
were reported for knee extension strength (3.3 and 2.4 Nm) and for knee 
flexion strength (2.1 and 2.5 Nm of the left and right limbs respectively). 
The patients were unable to lift the reported intensities of healthy studies 
(67 - 80% max strength) yet they were able to perform the same volume by 
performing more repetitions using lower weights. Chetlin et al. (2004) 
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suggested that if higher weights were used the increases in strength may 
have been statistically significant. However, due to moderate intensity 
exercises being associated with increasing the risk of performance 
decrements in neuromuscular patients a lower intensity was assumed. 
The lack of significant effects as a result of combined CrM and RT 
are also seen in studies involving healthy individuals. Bermon et al. (1998) 
found no benefits in six weeks of heavy RT and CrM supplementation in 
older individuals. Eijnde et al. (2003) tested forty-six men aged 55 - 75 
years over a six month period in a double blinded fashion and found no 
benefit to combining two - three session of RT a week with five0g.d- 1 of 
CrM over six months in older individuals. Possibly a different 
supplementation programme and/or training regimen need to be developed 
along with intensity, frequency and duration of the exercises performed. 
However not all studies show nonsignificant increases in strength. 
Chrusch et al. (2001) reported significant increases in muscular strength of 
men aged >60 years old after twelve-weeks of RT and CrM 
supplementation. Brose, Parise and Tamopolsky (2003) also found 
significant increases in muscular strength after fourteen weeks of RT and 
supplementation. Isometric PT values for knee extension, increased by 25% 
by the final week as a result of the exercise and supplement combination. 
It is believed that these small strength increases could be due to 
changes in the neural functioning of different muscles involved. It has also 
been stated that neural adaptations are a result of strength increases in 
novice lifters opposed to hypertrophy, which accounts for major gains in 
trained individuals (Volek et al., 2004). It is not exactly known how these 
changes in protein expression elicit strength gains however it is possible 
that the intramuscular restructuring could be a contributing factor 
(Evetovich et al., 2001). 
Insignificant strength increases could also be due to a learning effect 
(Gilliam, Hohzom, Martin & Trimble, 2000). Once the muscles adapt to the 
type of training fairly small increases, if any, are reported (Evetovich et al., 
2001 ). Another reason for insignificant increases could be due to the low 
subject numbers and the type of training employed, especially in the case of 
isometric strength gains. 
76 
Training normally incorporates lifting free weights at low intensities 
making it possible for the strength measures in patients to benefit from 
isokinetic testing greater than isometric training as this can induce strength 
changes at higher and/or lower angles than the angles tested (Chetlin et al., 
2004). Another explanation for the small increases could be due to the 
comparison of data between three different isokinetic dynamometers. The 
ICC's of a comparative study (see Appendix H) involving 22 individuals 
(11 males and 11 females) on all three isokinetic dynamometers used were 
not reliable for isometric (Cybex = 0.64 - 0.89; B2 = 0.80 - 0.90; B3 = 
0.84 - 0.92) and isokinetic (Cybex = 0.81 - 0.92; B2 = 0.77 - 0.93; B3 = 
0.92 - 0.97) extension exercises. Therefore, the differences between 
machines could also be the cause of insignificant values. 
In addition CrM has been shown not to increase muscular function 
due to the actual training workloads being insufficient (i.e. 20 - 30 RM). 
It's previously been reported that higher, more demanding workloads (5 -
10 RM) are necessary to produce muscle changes in elderly individuals 
(Eijnde et al., 2003). Therefore if subject numbers, training volumes 
(possibly the number of repetitions for the patients), training intensity and 
the loading phase of CrM were increased, greater changes may have been 
detected. However, considering the target population low training 
intensities and volumes were adapted to suit the nature of the IM. 
5.4 Body Composition (DEXA) 
In the present study whole body mass and limb segment mass did not 
differ greatly. The LBM increased (CG = 2 kg; MCG = 3.4 kg; PG = 1.1 kg) 
for the whole body data as well as for the trained (CG = 0.3 kg; MCG = 
0.5 kg; PG = 0.4 kg) and untrained (CG = 0.2 kg; MCG = 0.6 kg; PG = 0.4 
kg) limb. Whole body FM increased for the MCG (1 kg) and decreased for 
the CG and PG (-0.4 kg and -1.1 kg respectively). Small decreases were also 
seen in the FM for the trained limb of the CG and MCG (-0.1 kg) and 
untrained (-0.3 kg). The PGU limb also decreased slightly (-0.2 kg) however 
the PGT limb increased (0.1 kg). 
Increases in body mass of approximately 0.7 - 1.6 kilogram are 
reported in most studies using CrM supplementation (Grindstaff et al., 
1997). It has been suggested that the circulation of total body water between 
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the intracellular and extracellular spaces can induce both protein and 
glycogen production (Ziegenfuss et al., 1998; Bemben et al., 2001a). 
Therefore DEXA procedures for the measurement of body composition are 
becoming more desirable in clinical practices as it can detect even the 
slightest changes in LBM and FM (Diessel et al., 2000). 
Volek et al. (2004) found that the Cr group gained more LBM than the 
placebo group, with results being significant in the increases of LBM for the 
legs ( + 1.6 kg). Over the four weeks LBM increased for total body 
measurements by 3.4 kilogram as a result of CrM supplementation and 
training. This increase above normal reported values could be due to the 
subjects having five years RT experience. As previously stated in 
experienced lifters the majority of strength gains can be attributed to 
hypertrophy of the muscles (Volek et al., 2004). Francaux and Poortmans 
(1999) found no changes in body mass for either the control or placebo 
groups, while a two kilogram increase in body mass was seen in the CrM 
group. Due to the absence of changes in extracellular and intracellular 
compartments the increases were attributed to LBM expansion (Francaux & 
Poortmans, 1999). 
Huso, Hampl, Johnston and Swan (2002) studied the effects CrM 
supplementation on substrate utilisation during twelve-weeks of RT and 
within three weeks of CrM supplementation, body mass increased 1.6 ± 0.5 
kilograms with no significant changes in the placebo trial. Significant 
increases in LBM were found after CrM and placebo ingestion (1.9 ± 0.8 and 
2.2 ± 0.7 kg, respectively) however FM did not change significantly with 
CrM supplementation and decreased significantly after placebo ingestion 
(2.4 ± 0.8 kg) (Huso et al., 2002). Stout et al. (2001) also performed a study 
on a patient with Myasthenia Gravis (age 26 yrs) to determine the effects of 
RT and CrM supplementation on body composition, training volume and PT 
strength. Increases in body mass (6.8%) and FFM (4.3%) were found with 
15 weeks of CrM supplementation and RT (Stout et al., 2001). 
The increase in body mass observed as a result CrM supplementation 
could be due to muscle hypertrophy, the structural change in the myofibrils, 
possibly due to increased protein synthesis or an increase in total body water 
(Balsom et al., 1993; Becque et al., 2000; Bemben et al., 2001a). Creatine is 
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believed to enter the intracellular space of a cell and by osmosis, a process 
by which a liquid is drawn from a weak solution to a more concentrated 
solution through a semi-permeable membrane, draws water within the cell 
(Lambert et al., 2003). Thus leading to increases in intracellular water, with 
little or no change to extracellular fluid, and total body water enhancing 
muscle volume (Ziegenfuss et al., 1998; Bemben et al., 2001a; Lambert et 
al., 2003). 
Body mass increases of up to two kilograms can normally be found 
with a CrM supplementation period of five to seven days. Due to the short 
period of supplementation and the sudden increase in body mass, increases 
in intracellular water are thought to be the cause rather than increases in 
protein synthesis, which is though to be the case in studies with a long 
supplementation period. However exact confirmation of this speculation is 
not presently accessible and other studies involving short term 
supplementation have suggested increases in LBM as a result of protein 
synthesis (Andres et al., 1999). 
Although there were increases m serum Cm values in the present 
study, these increases may not have been adequate enough to influence 
muscle mass. A longer supplementation and training period, increased 
subject numbers, the employment of whole body RT as opposed to lower 
body exercises and diet restrictions throughout the entirety of the study could 
have seen greater differences and possibly even significant differences in 
body composition of the patient populations. However this study was 
implemented for use in specific patient populations in which no true set of 
exercise guidelines or knowledge of the effects of diet restrictions are 
available. It was also designed to test the simplicity and practicality of use at 
home, so that it could be performed safely without supervision and without 
expensive equipment. 
5.5 Creatinine 
In the present study serum Cm values increased for the PG (14.9%), 
the MCG (9.9%) and for the CG (15%) over the twelve-weeks. Baseline 
figures only differed by 11.5% between the PG and CG and 17. 7% between 
the PG and MCG. In Week 12 the PG differed by 11.5% and 12.6% 
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between the CG and MCG respectively. Elevated serum Cm values in both 
the PG and CG suggest that intramuscular Cr concentrations were 
increased. 
Chetlin et al. (2004) found increases of 1 0  mmol.kg- 1 in patients with 
Charcot Marie Tooth disease did not improve performance however 
increased intramuscular concentrations of Cr by 7%. Volek et al. (2004) 
reported significant increases of 5 .8% in plasma Cm in a Cr group 
compared with no changes in a placebo group of healthy subjects. 
Following CrM supplementation, intramuscular Cr is broken down 
into Cm. Increases in Cm values post loading have been suggested to be the 
result of enhanced Cr turnover and/or an ability to maintain improved 
training volumes (Kreider et al., 2003). Increase of 20 mmol.kt 1 of muscle 
Cm is said to be due to CrM supplementation, which can provoke increases 
in exercise performance (Greenhaff, 1 997). 
The small increases seen in each study is likely due to the larger 
concentrations of muscle Cr levels after supplementation (Volek et al. ,  
2004). Increases in Cm levels suggest that the CrM ingested was absorbed 
and metabolised. Again the lack of subject numbers and the absence of 
muscle biopsies reduce the possible significant effects that could have been 
seen. 
5.6 Limitations 
The major limitation of this study is that only a small number of 
subjects were obtained, reducing the potential power and statistical 
significance of the results. In addition there is a limited number of 
controlled studies available for PM and DM, and those that have been 
reported also used insignificant numbers (Choy & Isenberg, 2002). 
Therefore the results of this study could not be compared with a large 
number of statistically significant studies. 
A further limitation was that both unnary Cr measurements and 
muscle biopsies were not analysed. Urinary Cr measurements were not 
attained and therefore the uptake of Cr into the body was not assessed. 
Muscle biopsies were not performed therefore the extent of muscle fibre 
depletion and regeneration could not be measured. 
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A restriction in the recruiting process was also a limitation. The study 
was limited to a selected population and the patients were in a dormant 
phase of their disease. The study also targeted subjects without a heavy RT 
background or recent CrM use in the last six months. 
However, despite these limitations the rationale behind the present 
study is very important and should be re-emphasised. There are not many 
reports of the benefits of exercise and CrM supplementation in special 
populations like PM and DM. The study shows that patient populations can 
exercise without fear of their disease flaring up as a result of activity. It also 
shows that supplementation with CrM was well tolerated and had no 
serious side effects that would have inhibited any improvements. Due to a 
lack of CrM supplementation and RT studies with PM and DM, the study 
was designed based on previous work with elderly individual so that 
training and supplementation could be easily followed and performed at 
home without supervision and the need for expensive equipment. For this 
reason, weights were employed at a low intensity and the subjects were 
allowed to progress individually. Overall, despite the lack of statistical 
significance in strength changes and the low participation numbers the 
study provides an encouraging foundation for future studies in this area. 
5.7 Conclusion 
The present study has shown that a light home-based RT programme 
performed in Cl)njunction with CrM supplementation can have a positive 
effect on muscle mass and muscular strength. Although the increases in 
strength were minimal, further research with a larger population and 
possibly a longer study period could potentially show greater significance in 
muscle function. Overall, the study showed that the employment of a safe 
exercise programme and the ingestion of CrM was not detrimental to the 
health or well being of individuals with PM and DM. 
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The Effects of Combined Creatine Monohydrate Supplementation and Physical Training on 
Body Composition and Muscular Function in Patients with Inflammatory Myopathies 
Volunteers needed ! ! !  
A i m :  -
This exercise program has been developed to ascertain whether 
supplementation of Creatine Monohydrate, linked with appropriate 
muscular training, will lead to an increase in lower leg muscle mass and 
strength in patients with Polymyositis and Dermatomyositis. 
Part i c ipants must  b e :  
• Healthy individuals 
Dermatomyositis 
and patients 
• Aged 30 - 80 years both males and females 
with Polymyositis or 
• With no previous history of any heart conditions or joint instability 
All information obtained throughout the study is confidential. If you are interested in 
participating or want to find our more regarding the study, please do not hesitate to 
contact me on: 
Lynda Murray 
Phone (W) : 6304 5073 
E-mail : l .murray@ecu.edu.au 
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E D I T H  C OWAN 
U N IVE RS I T Y  
PERTH WESTERN AUSTRALIA 
JOONDALUP CAMPUS 
Lynda Murray B.Sc (Sports Science) 
Exercise Physiology Masters Candidate 
School of Biomedical & Sport Science 
Telephone: +6 1 8 6304 5073 
E-mail: 1 .murray@ecu.edu.au 
Informed Consent Form 
The Effects of Combined Creatine Monohydrate Supplementation and Physical Training on 
Body Composition and Muscular Function in Patients with Inflammatory Myopathies 
Thank you for your recent interest in participating in an exercise study looking into 
muscular strength. My name is Lynda Murray and I am a Masters student at Edith 
Cowan University. The purpose of this study is to investigate the responses of muscle to 
strength training while taking a dietary supplement under the supervision of Mike 
Newton. Please take a few minutes to read the following. 
A twelve-week program has been developed to ascertain whether supplementation of Creatine 
Monohydrate (CrM), linked with appropriate muscular training, would lead to an increase in muscle 
mass and strength in knee extensors and flexors in patients with Polymyositis and Dermatomyositis. 
During the twelve-weeks you will be asked to ingest CrM. Creatine (Cr) is a form of amino acid 
produced in the liver, pancreas and kidneys, which can be found in meat, eggs, fish and poultry. A 
loading phase (first two weeks) and a maintenance phase ( 1 0  weeks) will be employed to maintain 
Cr levels throughout the twelve-weeks. The CrM will be packed in sealed bags and proper 
instructions will be given to you on how to use and measure the supplement at home. 
Training will also be home-based and consist of you lifting one leg (this will be determined by the 
examiner) with an ankle cuff to provide weighted resistance. As an increase in the ease of your 
training is noticed, the amount of reps and/or weight will be increased slightly. Training will last no 
more than five minutes and be conducted three times a week for twelve-weeks. 
Strength of your lower leg will be measured using a Cybex 6000 or a Biodex isokinetic 
dynamometer. There are three main tests. The first test involves you pushing against an immovable 
object at two varying angles. The second test involves you extending (lifting) and flexing (lowering) 
your lower leg as hard as you can four times at four different angles. These two tests last only a few 
seconds each, with adequate rest stops between them. The last test is an endurance test lasting about 
three minutes. In each of these tests, strength of the lower leg will be recorded. The entire procedure 
will take no more than one hour if everything goes to plan. There will be five testing sessions taking 
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place over the twelve-weeks (baseline, 1 st week, 2nd week, ?1h week and in the last week). During this 
time if you wish to stop the session for any reason, we will stop without prejudice. Testing will be 
carried out in Building 1 9  room 150 at Edith Cowan University in Joondalup and/or at UWA. 
Finger prick blood samples will be obtained as well as x-rays from a machine called a Dual energy 
x-ray absorptiometry (DEXA). The DEXA scan is a non-invasive technique, which exposes your 
body to a very low level of radiation ( 1 .5 - 5 millirems) to determine your body composition. These 
x-rays will be taken of each thigh and will take approximately 20 minutes to obtain. Both the x-rays 
and the blood samples will be carried out before the supplementation and training program begins 
and again in week 1 2. 
I hope that this research will help reduce the severity of the disease, improve muscular function in 
older populations and improve the lifestyle of this population by making physical pursuits more 
enjoyable. For the purposes of this study, you will receive a free strength assessment. On completion 
of the study, you will be reimbursed $40 for the time spent training at home and for any travelling 
cost incurred. 
You should be aware that this study is not part of your clinical treatment and you should not stop any 
medication or any other treatment as a result of participation. Please refrain from any physical 
exercise and alcohol consumption at least 24 hours before commencing each test, refrain from 
caffeine drinks at least 4 hours before each test and please keep to your normal activity level 
throughout the entire time you are involved in the study. If you have any history of claustrophobia, 
heart conditions, joint instability or muscle strain, please volunteer for this study however you may 
be excluded from participating. 
As a result of participation, a few side effects may or may not occur. Temporary bloating or the 
feeling of fullness may result as a consequence of the supplement, temporary soreness from the 
fingertip pinprick blood sample may also occur. If you follow the correct dosage and maintain your 
hydration levels the risk of these side effects occurring is very low. Muscular soreness and/or fatigue 
may result as a consequence of the training program and strength testing. In the incidence of muscle 
soreness, the tenderness should only last one day and be very minimal. However, should you suffer 
from any muscle soreness beyond this period or any other problems please notify the principle 
researcher and the appropriate steps will be taken as you are covered by the ECU School of 
Biomedical and Sport Science Medical Insurance Policy. 
All written documents will be kept in a secure place and electronic documents will be backed up on 
disc and kept under lock and key in a secure room at SCHG and/or at ECU Joondalup. One copy of 
the original data will be archived in a secure storage area at ECU Joondalup for a period of at least 
five (5) years. Access to codes that may identify individuals and/or results will be restricted to my 
supervisors (Mike Newton & Prof. Frank Mastaglia) and myself. This study will also comply with 
the principles set out by the National Health and Medical research Council. 
NB: Please wear appropriate clothes for physical activity (shorts) and make sure you wear a pair of long socks. 
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For Further questions or information about the study please feel free to contact me, Lynda 
Murray on (08) 6304 5073 or 1 .murray@ecu.edu.au or my supervisor Mike Newton on 
(08) 6304 596 1 .  
If you would like to contact an independent person: 
Assoc. Prof. Barry Gibson 
Faculty of Computing, Health and Science 
Edith Cowan University 
l 00 J oondalup Drive, 
Joondalup, Western Australia 6027 
(08) 6304 5037 
OR 
Dr Susan Walters 
Centre of Neuromuscular and Neurological Disorders, 
University of Western Australia, QEII Medical Centre, 
Nedlands, Western Australia 6009 
(08) 9346 3980 or Susan.Walters@health.wa.gov.au 
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Consent Form 
The Effects of Combined Creatine Monohydrate Supplementation and Physical Training on 
Body Composition and Muscular Function in Patients with Inflammatory Myopathies 
I (the participant) have read and understand the above information form, which explains the 
nature of the study, the risks and advantages of participating. Any questions I had have been 
explained to my full satisfaction. 
I agree to take part in this study, however, I understand that I am free to withdraw at any time 
without prejudice to my medical treatment, if any. 
I understand that all information provided is treated as confidential and will not be released by 
the investigator unless required to do so by law. I agree that the research data obtained from the 
result of the study may be published and held for a period of time provided I am not identifiable. 
I ___________ , agree to participate as a subject in this study. 
(Please Print) 
Signature : ___________ _ Date:  ----------
Witness : - -----------
(Please Print) 
Witness Signature :  _________ _ Date:  ----------
Investigator : ------------ - Date:  ---- ------
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Health Screening Questionnaire 
The Effects of Combined Creatine Monohydrate Supplementation and Physical Training on Body 
Composition and Muscular Function in Patients with Inflammatory Myopathies 
To assist us with this check up please complete this health-screening questionnaire. Read the questions 
carefully and answer each one honestly: Tick yes or no. 
Yes No 
1 .  Are you currently suffering from any illness? If so provide details, (type and severity) D D 
2. Has your doctor ever said you have a heart condition and that you should only do physical D D 
activity recommended by a doctor? 
3 .  Do you feel pain in  your chest when you do physical activity? D D 
4. Do you lose balance because of dizziness? Do you ever lose consciousness? D D 
5. Do you currently have any (upper/lower limb) injuries? If so provide details: D D 
6. Do you have symptoms of (bone / joint I muscle) (stiffness / swelling / pain), which may D D 
limit your physical activity? If so provide details: 
7. Are you a vegetarian? D D 
8. Do you drink coffee or tea? How much? _ Cups/day. D D 
9. Do you drink alcohol? How much? _ Drinks/day. D D 
1 0  I s  your doctor currently prescribing drugs for your blood pressure o r  heart condition? I f  so D D 
please comment, (supplement and dosage): 
1 1 . Are you currently taking any other medication? If so please comment: D D 
12. Do you know of any other reason why you shouldn't do any physical activity? D D 
I have read, understood and completed this questionnaire. Any questions I had were answered to my full 
satisfaction. 
Name . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . Date . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Signature . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Investigator . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . Date . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  .
Doctor' s  Name . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . Date . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  .
Signature . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . (If applicable) 
The Sir Charles Gairdner Hospital Human Research Ethics Committee and Edith Cowan University Ethics 
Committee have given ethics approval for the conduct of this project. If you have any ethical concerns regarding the 
study you can contact the secretary of the SCGH Human Research Ethics Committee on (08) 9346 2999 or ECU 
Ethics Committee on (08) 9273 8492. 
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Timetable 
Week Supplementation Training Data obtained 
0 Meeting with the 
campus Doctor 
Pre Baseline: 
Cybex 
1 Loading phase 5 minutes per day / Baseline: Cybex 
(20 g.d- 1 ) 3 times a week Pre Values: Blood 
Cm & DEXA 
2 Loading phase 5 minutes per day / Week 2 :  Cybex 
(20 g.d- 1) 3 times a week 
3 - 6  Maintenance Phase 5 minutes per day / 
(5 g.d- 1 ) 3 times a week 
7 Maintenance Phase 5 minutes per day / Week 7: Cybex 
(5 g.d- 1 ) 3 times a week 
8 - 1 1  Maintenance Phase 5 minutes per day / 
(5 g.d- 1) 3 times a week 
1 2  Maintenance Phase 5 minutes per day / Week 12 :  Cybex 
(5 g.d- 1 ) 3 times a week Post values: Blood 
Cm & DEXA 
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Exercise & Diet Questionnaire 
The Effects of Combined Creatine Monohydrate Supplementation and Physical Training on 
Body Composition and Muscular Function in Patients with Inflammatory Myopathies 
For the completion of this study and to assist us with your results please complete the 
following questionnaire. Please read the questions carefully and answer each one 
honestly. 
1 .  Evaluate your motivation throughout the study. 
Poor D Satisfactory D Good D Excellent D 
2. Describe an example of the exercise you normally performed in one week. Please 
record al l types physical activity and for how long, e.g. Two hours heavy/light 
gardening, one hour house cleaning, 30 min slow/fast walking. 
Monday: ___ _ _ __ _ __________________ _ 
Tuesday: ___________________ _ ________ _ 
Wednesday: _ _ _ _ ____________________ ___ _ 
Thursday: _________ _ __ _ _ _ _ ____________ _ 
Friday: ______________________ _ _ ____ _ 
Weekend: --------------------- ---------
3 .  Evaluate your diet during your participation in the study. 
Poor D Satisfactory D Good D Excellent D 
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4.  Describe an example of the foods you normally eat in one week. Please record all 
types of meals, snacks and drinks, e.g. one glass of OJ, two slices of toast with 
butter and jam for breakfast. Evaluate your diet during your participation in the 
study. 
Monday: -----------------------------
Tuesday: -----------------------------
Wednesday: - -- - -- - ---- ---- - -- - ---- ----
Thursday: - - - - - ----- --- - -- - -- - ---- ---
Friday: ____ _________________________ _ 
Weekend: --- --------------------------
I have read, understood and completed this questionnaire. 
Name: Date: ------------ -------
(Please Print) 
Signature: __________ _ 
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1 1 1  
Name : Joe Citizen 
Week 1 
Monday 
Date : 
Tuesday 
Date : 
Wednesday 
Date : 
Thursday 
Date : 
Friday 
Date : 
Saturday 
Date : 
Sunday 
Date : 
Comments : 
REP 
Training Diary 
ID : LMTEST# 
Set Weight 
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H.1 Pilot Study 
H. 1 . 1  Background 
Isokinetic dynamometry is extensively used in the rehabilitation fields 
for training and research (Iossifidou & Baltzopoulos, 1 998). Hislop and 
Perrine were one of the first to introduce the concept of isokinetic 
contractions in the late 1 960's (Pincivero, Lephart & Karunakara, 1 997; 
Ling, Chen & McDonough, 1 999). The Cybex was the first model to be 
made, since then difference manufacturers have developed other devices for 
muscular testing and rehabilitation (Ling et al., 1 999). 
Isokinetic dynamometry allows for a predefined speed during 
exercise, speeds from 5 - 500° s- 1 can be performed (Dickhuth, 1 994). 
Isokinetic dynamometers also provide the ability to test isolated muscle 
groups and data such as torque, work, power and endurance can be recorded 
through a built-in software database (Wilson, 1 994). 
Establishing the reliability of the isokinetic dynamometer is very 
important as it determines the consistency and credibility of the data it 
produces (Drouin, Valovich-mcLeod, Shultz, Gansneder & Perrin, 2003). 
To obtain true measures, dependable and consistent measurement 
techniques, such as the dynamometer itself, the protocol implemented, the 
procedure to which it is carried out and the constancy of the individuals 
participating need to be employed (Lund et al., 2005). 
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Previous studies have found measures of torque to be reliable for 
various kinds of isokinetic dynamometers, such as the Cybex (Gross, 
Huffman, Phillips & Wray, 1 99 1 ;  Kannus, 1 992; Li, Wu, Maffulli, Chan & 
Chan, 1 996; Dolny, Collins, Wilson, Germann & Davis, 200 1), B2 (Feiring, 
Ellenbecker & Derscheid, 1 990; Gross et al., 1 99 1 ;  Brown, Whitehurst, 
Bryant & Buchalter, 1 993; Pincivero et al., 1 997; Iossifidou & 
Baltzopoulos, 1 998) and the B3 (Drouin et al. , 2003; Lund et al. ,  2005) 
isokinetic dynamometers. Few studies comparing data information between 
different isokinetic dynamometers expose problems in relation to the design 
of the dynamometer or the differences in the computer software (Drouin et 
al., 2003; Lund et al. ,  2005). As a result, a comparison between isokinetic 
dynamometers is necessary when reporting measures from more than one 
dynamometer (Lund et al . , 2005). 
H. 1 .2 Purpose of the Study 
The aim of the study was to evaluate the reliability of the Cybex 6000, 
B2 and B3 isokinetic dynamometers and compare flexion and extension of 
the knee with isometric and isokinetic exercises between dynamometers. 
H. 1 .3 Subjects 
22 healthy volunteers (1 1 = males, 1 1  = females) were recruited from 
the student population at ECU. Both males and females were required to 
read and sign a consent and medical form before commencing the study. 
Subject characteristics can be seen in Table 1 .  
Table 1 .  
Characteristics for the Pilot Study Participants 
Group 
Male (n = l l ) 
Female (n = 1 1 ) 
Total (n = 22) 
Age (yrs) 
23.9 ± 2 .7 
22.0 ± 2.4 
23.0 ± 2.6 
Note. Values are mean ± SD 
Height (cm) 
1 78.2 ± 4.5 
1 66.0 ± 8. 1  
1 72. 1 ± 8.9 
Weight (kg) 
75.3 ± 9.2 
66.5 ± 8.2 
70.9 ± 9.6 
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H.1.4 Isokinetic Dynamometer Protocol 
Each dynamometer was set up and calibrated prior to commencing the 
test, similar to the main study. The subjects were instructed verbally of the 
aims and practical procedures of the test in the first session and 
anthropometric measurements were measured and recorded. The 
dynamometer was then adjusted to ensure each subject was individually 
aligned with the dynamometer. These measurements were noted for 
reproduction at their next test. Practice tests were again employed until the 
subject was comfortable with the different tasks. A similar protocol to the 
master study was used although the endurance test was not applied. Each 
subject had to perform three isometric contractions at two different angles 
(45° and 60°) with a 30-second rest period between each angle. To account 
for any familiarisation within the short period of testing a second exercise at 
45° was included two minutes following the isometric test. 
The subjects were then instructed to perform four MVC's from slow 
to fast at constant angular velocities 60°, 120°, 180° and 240° s- 1 with a 30-
second rest intervals and again at 60° s - I following a two minute rest. After a 
short break the protocol was repeated with the other leg. The procedure was 
repeated twice on each isokinetic dynamometer within a period of three 
weeks. The dynamometer sequence was randomly chosen for each subject, 
as was their first testing leg, to help eliminate extraneous variables. 
H.1.5 Statistics 
Torque was recorded for isometric exercises. Torque, TW and ROM 
were recorded for isokinetic exercises and were tested for significance in a 
similar fashion to the master study. A t-test design was used and standard 
statistical methods were used to calculate the mean, SD or SEM and ICC. 
Differences were considered significant if the p value was < 0.05. The 
results were classed highly reliable with an ICC of r > 0.90 and reliable with 
an r-value of > 0.80. An r-value of 0.69 or less meant that the results were 
poor (Fenter et al., 2003). 
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H. 1 .6 Results 
Figure 1 below represents the isometric PT values for the extensors 
(left and right) at 45 ° and 60° for each isokinetic dynamometer. The B2 
dynamometer produced slightly lower PT values for both left and right 
limbs at 45 ° (Left = 1 29 . 7  ± 7 .4 Nm; Right = 1 1 8 . 1  ± 6 .4 Nm) and 60° (Left 
= 1 42 . 9  ± 8 . 8  Nm; Right = 1 40 .5  ± 8 . 5  Nm). The B3 however recorded 
similar PT values to the Cybex, in relation to angle and legs. The Cybex 
averaged 1 68 . 1 ± 9 .2 Nm for the left and 1 59 ± 9 .2 Nm for the right at 45 ° , 
and 208 .6  ± 1 2 . 5  Nm and 1 88 .7  ± 1 1 . 1  Nm respectively at 60° . The B3 was 
slightly more reliable at 45 ° (Left = 1 70 . 1 ± 8 . 7  Nm; Right = 1 70 . 1 ± 
9 .4 Nm) and 60° (Left = 202 .6  ± 1 1  Nm ; Right = 1 97 . 7  ± 1 0 .6 Nm) . Overall 
the B2 was found to be more consistent (lower SEM' s) however produced 
lower PT than the Cybex and B3 . 
240 
200 
Peak 1 60 
torque 
(Nm) 1 20 
80 
45 60 
Angle (degrees) 
� Cybex Left 
- Biodex 2 Left 
Biodex 3 Left 
� Cybex Right 
-ilE- Biodex 2 Right 
_._ Biodex 3 Right 
Figure 1 .  Isometric PT values for the extensors on the Cybex, Biodex 2 and 
Biodex 3 Dynamometers at 45 ° and 60° . 
Figure 2 represents the isometric PT values for the flexors (left and 
right) at 45 ° and 60° for each i sokinetic dynamometer. At 45 ° isometric the 
Cybex produced similar PT (Left = 1 02 .4  ± 7 .2  Nm; Right = 1 03 .4 ± 
1 20 
7 .2  Nm) to the B3 dynamometer (Left = 1 02.2 ± 7 .2 Nm; Right = 1 00 .6 ± 
6 .2 Nm) . However, B2 produced lower PT values (Left = 67. 1 ± 4 .9  Nm; 
Right = 76 ± 4.6 Nm) . There was a larger variation between the three 
machines at 60° isometric . The Cybex produced the highest and most 
reliable PT (Left = 9 1 . 1  ± 6 . 7  Nm; Right = 93 . 1  ± 6 . 5  Nm) followed by B3 
slightly lower. The B3 tended to  generate lower torques than the Cybex in 
this case. Again the B2 (Left = 57 .9  ± 4.3 Nm; Right = 67 .9 ± 4 .3  Nm) was 
more constant (lower SEM' s) however produced lower torques than the 
Cybex and B3 .  
200 
1 60 
Peak 1 20 
torque 
(Nm) 80 
40 
� Cybex Left 
- Biodex 2 Left 
____._ Biodex 3 Left 
---*- Cybex Right 
___.._ Biodex 2 Right 
� Biodex 3 Right 
0 -t-------�--------, 
45 60 
Angle (degrees) 
Figure 2. Isometric PT values for the flexors on the Cybex, Biodex 2 and 
Biodex 3 Dynamometers at 45 ° and 60° . 
Figure 3 represents the isokinetic PT values for the extensors (left and 
right) at 60, 1 20,  1 80 and 240° s- 1 for each isokinetic dynamometer. A more 
consistent trend was seen in the isokinetic MVC' s  at 240° f 1 than at 60° s- 1 • 
Similar findings were found in the left leg as in the right leg, across the 
velocities and machines .  At 60° s- 1 the Cybex produced closer PT (Left = 
1 70 . 7  ± 8 . 5  Nm; Right = 1 69 .3  ± 1 0  Nm) to B2 (Left = 1 67 ± 8 . 5  Nm; Right 
= 1 67 . 3  ± 1 0  Nm). At 1 20° f 1 both the Cybex (Left = 1 40 .4 ± 8 . 5  Nm; Right 
= 1 3 8 . 7  ± 8 . 7  Nm) and B2 (Left = 1 39 .6 ± 8 . 5  Nm; Right = 1 3 8 . 7  ± 8 . 7  Nm) 
increased. The B3 was slightly lower at 60° s- 1 (Left = 1 60 . 5  ± 8 . 5  Nm; 
1 2 1  
Right = 1 60 . 1 ± 9 .6 Nm) and 1 20° s- 1 (Left = 1 33 . 8  ± 7 . 7  Nm ; Right = 1 34 .3  
± 8 .8  Nm) .  The higher the velocity the more constant the PT became for the 
left (Cybex = 1 1 7 .2  ± 6 .4 Nm ; B2 = 1 1 7 . 5  ± 6 . 8  Nm; B3 = 1 1 3 . 7  ± 7 Nm) 
and right legs (Cybex = 1 1 5 ± 7 . 1 Nm ; B2 = 1 1 9 .2  ± 7 . 3  Nm ; B3 = 1 1 6 . 5  ± 
7 .9  Nm) at 1 80° s- 1 , and again for the left (Cybex = 1 0 1 . 5 ± 6 .6 Nm ; B2 = 
1 05 .2 ± 6 . 1 Nm; B3 = 1 02 .6  ± 6 .7 Nm) and right (Cybex = 1 03 ± 7 .2 Nm; 
B2 = 1 04 . 1 ± 6.4 Nm; B3 = 1 04 .4 ± 7 . 1 Nm) legs at  240° s- 1 • 
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Figure 3. Isokinetic PT values for the extensors on the Cybex, Biodex 2 and 
Biodex 3 Dynamometers at 60, 1 20, 1 80 and 240° s- 1 • 
Figure 4 represents the isokinetic PT values for the flexors (left and 
right) at 60, 1 20, 1 80 and 240° s- 1 for each isokinetic dynamometer. The B3  
performed the greatest PT  at 60, 1 20, 1 80 and 240° s- 1 for the left (60° s- 1 = 
97 . 1 ± 5 .4 Nm ; 1 20° s- 1 = 86.4 ± 5 . 3  Nm ; 1 80° s- 1 = 79. 5 1 ± 5 . 1  Nm; 
240° s- 1 = 73 . 5  ± 4 . 7  Nm) and the right legs (60° s- 1 = 95 .2 ± 5 .4 Nm;  
1 20° s- 1 = 84 .2  ± 5 . 3  Nm; 1 80° s- 1 = 76 .5  ± 4 . 5  Nm;  240° s- 1 = 7 1 .2 ± 
4.4 Nm) .  The Cybex and B2 generated lower torques then the B3 . The 
Cybex performed slightly better on average (Left = 9 1 . 3  ± 6 . 35  Nm ; Right = 
93 .3  ± 6.9 Nm) compared with B2 (Left = 8 5 . 5  ± 6 Nm; Right = 9 1 .9 ± 
6 .6  Nm) at 60° s- 1 and at 1 20° s- 1 (Cybex Left = 78 .2  ± 6 .3  Nm; Right = 78 . 3  
1 22 
± 6 .3 Nm; B2 Left = 74 . 8  ± 6 Nm; Right = 77 .2 ± 5 .9 Nm). At 1 80° s- 1 both 
Cybex and B2 were fairly similar (Cybex Left = 66.6 ± 5 .3 Nm; Right = 
68 .4 ± 6 Nm; B2 Left = 66.3 ± 5 .4 Nm; Right = 70 .3 ± 5 . 3  Nm) . At 240° s- 1 
B2 was slightly higher (Left = 60. 5 ± 5 . 1  Nm ; Right = 63 . 8  ± 4 .9  Nm) than 
the Cybex (Left = 59 .3  ± 5 .2 Nm; Right = 60.4 ± 5 . 7  Nm) .  
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Figure 4. Isokinetic PT values for the flexors on the Cybex, Biodex 2 and 
Biodex 3 Dynamometers at 60, 1 20, 1 80 and 240° s- 1 • 
Figure 5 represents the isokinetic TW values for the extensors (left 
and right) at 60, 1 20, 1 80 and 240° s- 1 for each isokinetic dynamometer. The 
B3 generated higher TW at 60, 1 20,  1 80 and 240° s- 1 for the left (60° s- 1 = 
1 62 . 8  ± 7 .8  J ;  1 20° s- 1 = 1 46 . 5  ± 7 . 5  J ;  1 80° s- 1 = 1 27 . 5  ± 7.4 J ;  240° s- 1 = 
1 1 0 .7 ± 7 . 3  J) and the right (60° s- 1 = 1 64 . 8  ± 8 . 5  J; 1 20° s- 1 = 1 46 .2 ± 9 . 1 J ;  
1 80° s- 1 = 1 28 .6  ± 8 J ;  240° s- 1 = 1 1 1 . 3 ± 7 .4 J) legs . The B2 generated 
slightly lower TW values for left (60° s- 1 = 1 5 1 . 8 ± 7 . 9  J; 1 20° s- 1 = 1 34 .7 ± 
7 .6  J ;  1 80° s- 1 = 1 1 7 .3 ± 6 .7  J; 240° s- 1 = 1 04 . 7  ± 6. 1 J) and right (60° s- 1 = 
1 49. 1 ± 8 .2  J; 1 20° s- 1 = 1 32 ± 7 .6  J; 1 80° s- 1 = 1 2 1 . 3 ± 7. 1 J ;  240° s- 1 = 
1 06 .8  ± 6 .4 J) legs. Overall the Cybex had the lowest TW values at 60° s- 1 
(Left = 1 5 1 . 1  ± 8 . 3  J; Right = 1 45 . 8  ± 6 .6  J), 1 20° s- 1 (Left = 1 3 1 . 9 ± 7 . 1 J ;  
1 23 
Right = 1 25 . 9  ± 6 . 3  J), 1 80° s- 1 (Left = 1 1 1 .9 ± 6 .2  J; Right = 1 08 . 7  ± 5 . 9  J) 
and 240° s- 1 (Left = 92.9  ± 6.4 J ;  Right = 9 1 .7  ± 5 . 8  J) . 
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Figure 5. Isokinetic TW generated by the extensors on the Cybex, Biodex 2 
and Biodex 3 Dynamometers at 60, 1 20,  1 80 and 240° s- 1 • 
Figure 6 represents the isokinetic TW values for the flexors (left and 
right) at 60, 1 20,  1 80 and 240° s" 1 for each isokinetic dynamometer. The 
Cybex on average generated the lowest TW over 60, 1 20, 1 80 and 240° s- 1 
for the left (60° s- 1 = 88  ± 6 .4 J ;  1 20° s- 1 = 74.4 ± 6.2 J; 1 80° s- 1 = 59 .6  ± 
5 . 5  J; 240° s- 1 = 48 ± 5 J) and right (60° s- 1 = 90.2 ± 6 .6  J ;  1 20° s- 1 = 92 .4 ± 
1 8  J; 1 80° s" 1 = 76 .9 ± 1 5 . 8 J ;  240° s- 1 = 65 . 8  ± 1 6  J) legs . Followed by B2 
for the left (60° s- 1 = 8 5 .6 ± 7 .3 J ;  1 20° s- 1 = 76 .8  ± 6 .7 J ;  1 80° s- 1 = 67 .7  ± 
5 . 8  J; 240° s- 1 = 59 .6  ± 5 .2 J) and right (60° s- 1 = 94.6 ± 6 .9 J ;  1 20° s- 1 = 1 00 
± 1 7 .7  J ;  1 80° s" 1 = 94. 5  ± 1 8 .6 J ;  240° s" 1 = 85 . 3  ± 1 8 .2 J) legs . The B3 
produced the highest TW values at 60° s- 1 (Left = 1 22 .2 ± 7 . 1 J ;  Right = 
1 08 .2  ± 6 .5 J) , 1 20° s- 1 (Left = 1 02 .4 ± 6 . 8  J ;  Right = 1 22 . 5  ± 23 .4 J), 
1 80° s- 1 (Left = 92 . 1 5  ± 6.8 J ;  Right = 1 1 1 . 5 ± 2 1 .2 J) and 240° s" 1 (Left = 
8 1 .4 ± 5 . 7  J ;  Right = 97 .3 ± 1 7 . 5  J) .  
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Figure 6. Isokinetic TW generated by the flexors on the Cybex, Biodex 2 
and Biodex 3 Dynamometers at 60, 1 20, 1 80 and 240° s- 1 . 
Figure 7 represents the isokinetic STW values for the extensors (both 
left and right legs) at 60, 1 20,  1 80 and 240° s- 1 for each isokinetic 
dynamometer. The Cybex generated the lowest STW values compared with 
B2 and B3 . At 60° s- 1 the left leg produced 554 . 5  ± 29 .6 J, 5 56  ± 29 .6  J and 
5 86 .6  ± 29 J, the right leg produced STW values of 534 .4 ± 24. 5  J, 545 . 8  ± 
29.9  J and 585 . 6  ± 32 J for the Cybex, B2 and B3 respectively. At 1 20° s- 1 
the left leg produced 466.3 ± 25 . 7  J, 487 .9  ± 29. 1 J and 5 1 4.7  ± 28 .6 J 
compared with 446 .2 ± 22 . 8  J, 468 . 1  ± 27 .8  J and 52 1 . 8 ± 35 .7 J for the 
right leg on the Cybex, B2 and B3 respectively. At 1 80° s- 1 the left leg 
generated 399 .8  ± 23 .3  J, 423 . 7  ± 26.4 J and 449.4 ± 29.4 J and for the right 
leg 376 . 1 ± 22 . 8  J, 427 .5  ± 25 .2 J and 45 1 . 8 ± 30 .8  J for the Cybex, B2 and 
B3 respectively. By 240° s- 1 the STW decreased to 324 ± 23 .6  J, 3 82 .4 ± 
22 .9  J and 396 .7  ± 28 .9  J for the left leg and 32 1 . 6 ± 23 J, 383 . 7  ± 24. 1 J 
and 3 9 1  ± 29 J for the right leg on the Cybex, B2 and B3 respectively. 
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Figure 7. Isokinetic STW produced by the extensors on the Cybex, B iodex 2 
and Biodex 3 Dynamometers at 60, 1 20,  1 80 and 240° s- 1 • 
Table 2 represents the within group measures for the two isometric 
trials at 45 ° on the Cybex, B2 and B3 .  The relationship between the two 
trials is highly reliable (Cybex = 0 .932 - 0 .974; B2 = 0 .920 - 0.986;  B3 = 
0 . 866 - 0.966) . 
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Table 2 
Reliability measures within isometric trials for PT at 45°. 
ICC 
Trial 1 
Extension 
Left 
Cybex 0.974 
B2 0.968 
B3 0.866 
Right 
Cybex 0.967 
B2 0.959 
B3 0.897 
Flexion 
Left 
Cybex 0.956 
B2 0.980 
B3 0.9 1 1 
Right 
Cybex 0.932 
B2 0.986 
B3 0.900 
Trial 2 
Extension 
Left 
Cybex 0.950 
B2 0.963 
B3 0.933 
Right 
Cybex 0.933 
B2 0.920 
B3 0.966 
Flexion 
Left 
Cybex 0.963 
B2 0.957 
B3 0.930 
Right 
Cybex 0.962 
B2 0.946 
B3 0.945 
Table 3 represents the within group measures for the two isokinetic 
trials at 60° s- 1 on the Cybex, B2 and B3 . PT and TW values are illustrates 
in the table for Cybex (PT = 0.730 - 0.955 ;  TW = 0.860 - 0.979), B2 (PT = 
0.901 - 0.963; TW = 0.876 - 0.989) and B3 (PT = 0.734 - 0.969; TW = 
0.876 - 0.993). 
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Table 3 
Reliability measures within isokinetic trials for PT and TW at 60 ° s-1 . 
ICC 
PT 60° TW 60° 
Trial 1 
Extension 
Left 
C 0.927 0.947 
B2 0.926 0.876 
B3 0.939 0.926 
Right 
C 0.730 0.860 
B2 0.932 0.935 
B3 0.734 0.901 
Flexion 
Left 
C 0.944 0.928 
B2 0.954 0.921 
B3 0.951 0.876 
Right 
C 0.891 0.979 
B2 0.963 0.989 
B3 0.880 0.993 
Trial 2 
Extension 
Left 
C 0.927 0.962 
B2 0.901 0.878 
B3 0.937 0.918 
Right 
C 0.929 0.910 
B2 0.918 0.938 
B3 0.935 0.899 
Flexion 
Left 
C 0.955 0.933 
B2 0.954 0.948 
B3 0.969 0.962 
Right 
C 0.912 0.978 
B2 0.952 0.962 
B3 0.953 0.988 
Table 4 represents the within group measures for STW and ROM of 
the two isokinetic trials at 60° s- 1 on the Cybex, B2 and B3. The STW is 
fairly reliable (Cybex = 0.799 - 0.919; B2 = 0.843 - 0.936; B3 = 0.760 -
0.891). Both B2 and B3 are not as reliable for the ROM as the Cybex 
dynamometer (Cybex 0.787 - 0.885; B2 0.591 - 0.972; B3 0.598 - 0.841). 
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Table 4 
Reliability measures within isokinetic extension trials for STW and range of 
movement at 60 ° s-1 . 
ICC 
STW ROM 
Trial 1 
Left 
C 0.883 0.787 
B2 0.843 0.591 
B3 0.784 0.773 
Right 
C 0.799 0.885 
B2 0.936 0.905 
B3 0.760 0.841 
Trial 2 
Left 
C 0.919 0.797 
B2 0.913 0.972 
B3 0.891 0.788 
Right 
C 0.841 0.805 
B2 0.867 0.951 
B3 0.825 0.598 
Table 5 represents PT between group measures for flexion and 
extension of the isometric trials at 45° and 60° on the Cybex, B2 and B3. 
The best value of the two trials at 45° was used for analysis. Peak torque is 
fairly reliable (Flexion = 0.823 - 0.949; Extension = 0.664 - 0.922). 
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Table 5 
Reliability measures between isometric trials for PT. 
ICC 
Flexion Extension 
45° 
Left 
C 0.894 0 .781 
B2 0.884 0.8 1 5  
B3 0.91 9  0.922 
Right 
C 0.865 0.886 
B2 0.949 0.801 
B3 0.909 0. 87 1 
60° 
Left 
C 0.862 0.784 
B2 0.836 0.895 
B3 0.890 0.835 
Right 
C 0 .823 0.664 
B2 0.922 0.896 
B3 0.938 0. 846 
Table 6 represents PT between group measures for flexion and 
extension of the isokinetic trials at 60, 1 20, 1 80 and 240° s- 1 on the Cybex, 
B2 and B3 .  PT is reliable (Flexion = 0.759 - 0.937; Extension = 0.765 -
0.97 1 ) . 
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Table 6 
Reliability measures between isokinetic extension andflexion trials for PT 
ICC 
Flexion Extension 
60° s-
Left 
C 0.933 0.841 
B2 0.9 1 5  0.925 
B3 0.925 0.9 1 8  
Right 
C 0.861 0.885 
B2 0.892 0.765 
B3 0.880 0.9 1 8  
1 20° s- 1 
Left 
C 0.759 0.8 1 1 
B2 0.870 0.787 
B3 0.928 0.946 
Right 
C 0.925 0.9 1 6  
B2 0.907 0.928 
B3 0.91 8  0.922 
1 80° f1 
Left 
C 0.885 0.924 
B2 0.934 0.908 
B3 0.884 0.954 
Right 
C 0.889 0.872 
B2 0 .881 0.93 1 
B3 0.920 0.926 
240° s- 1 
Left 
C 0.92 1  0.873 
B2 0.923 0.906 
B3 0.937 0.971 
Right 
C 0.825 0.880 
B2 0.852 0.9 1 8  
B3 0.89 1 0.924 
Table 7 represents TW between group measures for flexion and 
extension of the isokinetic trials at 60, 120, 1 80 and 240° s- 1 on the Cybex, 
B2 and B3. The TW is fairly reliable (60° s- 1 = 0.645 - 0.930; 1 20° s- 1 = 
0.61 7  - 0.987; 1 80° s- 1 = 0.696 - 0.97 1 ; 240° s- 1 = 0.679 - 0.978). 
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Table 7 
Reliability measures between isokinetic extension and flexion trials for TW 
ICC 
Flexion Extension 
60° s-
Left 
C 0.904 0.854 
B2 0.78 1 0.645 
B3 0.930 0.876 
Right 
C 0.833 0.759 
B2 0.765 0.784 
B3 0.890 0.786 
1 20° s- 1 
Left 
C 0.861 0.8 1 9  
B2 0.764 0.6 1 7  
B3 0.914  0.876 
Right 
C 0.987 0.875 
B2 0.961 0.666 
B3 0.961 0.895 
1 80° s-1 
Left 
C 0.799 0.880 
B2 0.867 0.696 
B3 0.898 0.874 
Right 
C 0.958 0.82 1  
B2 0.971 0.742 
B3 0.948 0.902 
240° s- 1 
Left 
C 0.886 0.88 1 
B2 0.8 1 5  0.679 
B3 0.872 0.9 1 5  
Right 
C 0.978 0.880 
B2 0.973 0.7 1 7  
B3 0.888 0.886 
Table 8 represents STW between group measures for flexion and 
extension of the isokinetic trials at 60, 1 20, 1 80 and 240° s- 1 on the Cybex, 
B2 and B3. The STW is not as reliable (range 0.5 1 9  - 0.892). Both B2 and 
B3 are not reliable for ROM (B2 = 0.258 - 0.465 ; B3 = 0.505 - 0.598) 
compared with the Cybex (range 0.599 - 0.858). 
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Table 8 
Reliability measures between isokinetic extension trials for STW and ROM 
ICC 
STW ROM 
60° s-
Left 
C 0.835 0.656 
B2 0.632 0.320 
B3 0.869 0.510 
Right 
C 0.668 0.837 
B2 0.722 0.465 
B3 0.780 0.570 
120° s- 1 
Left 
C 0.785 0.623 
B2 0.597 0.307 
B3 0.814 0.543 
Right 
C 0.779 0.765 
B2 0.700 0.359 
B3 0.871 0.582 
180° s- 1 
Left 
C 0.799 0.669 
B2 0.519 0.299 
B3 0.850 0.514 
Right 
C 0.772 0.858 
B2 0.787 0.376 
B3 0.838 0.570 
240° s- 1 
Left 
C 0.861 0.599 
B2 0.614 0.258 
B3 0.877 0.505 
Right 
C 0.829 0.852 
B2 0.728 0.395 
B3 0.892 0.598 
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H.1. 7 Discussion 
Our findings demonstrate that neither of the isokinetic dynamometers 
is comparable with each other for isometric torque, slow and high velocity 
torques, TW or ROM. 
Isometric PT was measured at 45° and 60° on each dynamometer for 
both left and right limbs. The degree of discrepancy between isometric PT 
values suggests the isokinetic dynamometers are not capable of producing 
valid measures for comparison. The largest difference was recorded between 
the B2 and B3 (31.1 % and 44.6%) for left and right limbs during extension 
and (52.3% and 32.3%) during flexion at 45°. 
Discrepancies were also observed as the angle changed from 45° to 
60° (Extension = 41.8% and 40.9%; Flexion = 32.7% and 17.8%). At 45° 
the Cybex and B3 produced the closest extension values for the left leg PT 
(difference = 1.2%). The right limb was less consistent with the Cybex and 
B3 being 7.3% apart. Flexion contractions were very similar at 45° (0.3% 
and 2.7%) for the left and right limbs. At 60° PT was 2.9% and 4.9% 
different between the Cybex and B3 . However flexion showed greater 
differences (15.6% and 14%). 
Assuming that each subject performed the exercises with the same 
amount of strength and motivation on each dynamometer the differences 
reported between machines should be accounted for when comparing 
results. The differences between left and right limbs could be due to the 
subjects being predominantly dominant on the right side. A larger variation 
is also seen in angles closer to 90° flexion therefore caution should also be 
taken with varying angles. 
Measures of isokinetic PT revealed the greatest amount of variation. 
These discrepancies were as large as 6% at 60° s- 1 , 4.7% at 120° s-1, 3 .7% at 
180° s- 1 and 3.6% at 240° s- 1 for extension exercises. Flexion on the other 
hand produced higher differences (60° s- 1 = 13.5%; 120° s- 1 = 15.6%; 
180° s- 1 = 19.4%; 240° s- 1 = 24.1 %). As seen in Figures 3 and 4 the 
measures over each velocity varied suggesting the dynamometers are 
unreliable at slower velocities compared with higher velocities for extension 
and unreliable for all velocities in the flexion exercises performed. 
1 34  
The biggest differences in TW were seen between the B3 and Cybex 
followed closely by the B2 isokinetic dynamometer. Slight differences were 
seen in the right limb for extension (60° s- 1 = 13.1%; 120° s- 1 = 16.1%; 
180° s- 1 = 18.9%; 240° s- 1 = 21.4%). The greatest variation was seen in TW 
for flexion (60° s- 1 = 27.5%; 120° s- 1 = 37.6%; 180° s- 1 = 54.6%; 240° s- 1 = 
69.7%). 
The main discrepancy in ROM was seen between the B3 and B2, 
followed by the Cybex. There seemed to be a constant difference between 
the B3 and B2 isokinetic dynamometers with a 25.1 % difference at 60° s- 1 , 
26% at 120° s- 1 , 26.5% at 180° s- 1and 26.7% difference at 240° s- 1 for the 
left limb and a similar pattern arose in the right (60° s- 1 = 21.3%; 120° s- 1 = 
19.5%; 180° f 1 = 19.2%; 240° s- 1 = 19.5%). 
Over the years changes have been seen in the control of acceleration 
and velocity from earlier versions of the Biodex isokinetic dynamometer 
(Feiring et al., 1990; Brown et al., 1993). Drouin, Valovich-McLeod, 
Shultz, Gansneder and Perrin (2003) was the first study to test the reliability 
of the B3. There is an abundance of literature on the reliability of the B2 
isokinetic dynamometer (Feiring et al., 1990; Gross et al., 1991; Brown et 
al., 1993; Iossifidou & Baltzopoulos, 1998; Drouin et al., 2003). Since the 
Cybex is now out of production only a few studies report the reliability of 
the Cybex and its earlier versions (Gross et al., 1991; Kannus, 1992; Li et 
al., 1996; Dolny et al., 2001). 
Feiring, Ellenbecker and Derscheid (1990) performed a reliability 
study on the B2 isokinetic dynamometer and found test re-test coefficients 
for PT at 60, 180, 240 and 300° s- 1 (range 0.82 - 0.98) to be quite high. 
Gross, Huffman, Phillips and Wray (1991) found ICC's ranging from 0.67 
to 0.97 for non-windowed PT and angular work at 60 and 180° s- 1 on the B2 
isokinetic dynamometer. Pincivero, Lephart and Karunakara (1997) also 
reported on the B2 and found results were reliable between PT, TW and 
average power at 60 and 180° s- 1 • The ICC's ranged from 0.88 - 0.97 and 
0.82 - 0.96 for 60 and 180° s- 1 respectively. 
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Brown, Whitehurst, Bryant and Buchalter (1993) investigated the 
reliability of the PT measures using the B2 isokinetic dynamometer. At 
450° s- 1 an average of 68.2 Nm and 72.1 Nm were observed on Day One 
and Two respectively. Between measures the correlation was r = 0.95. 
However the test did not state the measurement validity therefore it is not 
known if the velocity was actually obtained in the MVC's performed 
(Drouin et al., 2003). 
Compared to a study by Drouin et al. (2003) using the B3 isokinetic 
dynamometer similar correlations between testing days were found. Drouin 
et al. (2003) stated that compared with their findings it seemed that the 
preselected velocity in Brown et al. (1993) study was not obtained. As the 
present study only assessed velocities as fast as 240° s- 1 the measurements 
can not be compared however it can be concluded that even though day to 
day reliability may be high, torque measurements between different 
isokinetic dynamometers are not always valid. 
Lund et al. (2005) also performed a reliability study on the B3 
isokinetic dynamometer and found it to be highly reliable and no learning 
effect even when comparing a retrial 20 minutes post or a week later. 
Drouin et al. (2003) stated that the B3 provides mechanically reliable PT 
measurements as well as position and velocity with same day trials and 
trials on different days. Drouin et al. (2003) also states that velocity 
measures up to 300° s- 1 are valid, however this decreases as the velocities 
increase. Li, Wu, Maffulli, Chan and Chan (1996) is the only study, to the 
author's knowledge, that tested the reliability of the Cybex 6000 model. The 
reliability of PT, TW and average power were measured. Peak torque was 
highly reliable (0.82 - 0.91), followed by TW (0.76 - 0.89) and average 
power (0.71 - 0.88). The knee extensors proved to be the most reliable as a 
result of test-retest variability and greater significance was seen at a velocity 
of 120° s- 1 (Li et al., 1996). 
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Torque measurements and performance in muscular activity can be 
affected by fitness levels, motivation, anxiety and position set up on test 
day. Other factors such as acknowledging the instructions, time of the day, 
visual and verbal feedback can also affect results (Lenaerts, Verbruggen & 
Duquet, 2001). Due to scheduling problems with timetables, time of day 
could not be controlled. Fitness levels varied due to the mix of males and 
females and the investigator tried to keep the emotional levels of motivation 
high and any anxiety low however different lifestyles may have been a 
contributing factor and was not controlled. 
Dynamometer set up was noted during every test day however minor 
changes were made for a few subjects mainly as a cause of subject 
discomfort. Studies have actually reported poor reliability when measuring 
lower extremity muscles because of the inability of testers to stabilise the 
dynamometer against explosive power (Fenter et al., 2003). This was quite 
evident on the B2. Position was controlled as much as possible. Visual and 
verbal feedback was present for every test day and protocol instructions 
were understood before participating. Protocol sequence was also strictly 
standardised and executed. 
H.1.8 Conclusion 
There are numerous isokinetic dynamometers on the market and the 
differences between these individual machines, even of the same model, can 
vary (Spencer, 2001 ). Results should only be compared with other isokinetic 
dynamometers with the same computer software (Drouin et al., 2003). The 
three isokinetic dynamometers used in this study continuously produced 
inconsistent values for PT and TW in isometric and isokinetic exercises. 
Comparing results from different models should always be avoided when 
testing any population. 
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